[
    {
        "pmid": "40818563",
        "title": "Genetically Tractable Rodent Models for Cryptosporidium hominis and C. parvum Infections: Identifying Differences in Infection Sites Between Host Species.",
        "abstract": "Cryptosporidiosis cause severe diarrhea child livestock However absence suitable rodent model led lack effective drug vaccines study genetically tractable rat mouse model developed two main cause human cryptosporidiosis Cryptosporidium hominis C parvum Neonatal mouse rat successfully infected two nonhuman primateadapted C hominis isolates one C parvum IId isolate resulting high oocyst shedding Using isolates tagged fluorescent protein luciferases enabled easy detection quantification oocyst shedding Cryptosporidium specie primarily infected ileum cecum colon neonatal mice contrast parasite primarily colonized duodenum jejunum neonatal rats specie responded treatment lysyltRNA synthetase inhibitor rat model Developing tractable animal model different infection site allow comparative study biology immunity major humanpathogenic Cryptosporidium species well evaluation potential drug vaccines",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818563/",
        "source_type": "Global"
    },
    {
        "pmid": "40816579",
        "title": "Safety and efficacy of Artemisia argyi extract RW0117 for functional dyspepsia: A randomized, double-blind, placebo-controlled clinical study.",
        "abstract": "Artemisia argyi A argyi herbaceous perennial plant long employed traditional medicine management gastrointestinal condition abdominal pain gastric ulcer diarrhea gastritis evaluate efficacy safety RW0117 ethanol extract A argyi alleviating symptom functional dyspepsia FD randomized doubleblind placebocontrolled clinical trial participant randomly assigned receive either one tablet RW0117 680 mgday containing 240 mg ethanol extract A argyi one placebo tablet 12 weeks primary outcome change baseline gastrointestinal symptomrating scale GSRS Secondary outcome included change baseline total GSRS score gastrointestinal symptom GIS Nepean Dyspepsia IndexKorean version NDIK score Functional Dyspepsiarelated Quality Life FDQoL adverse events study showed five individual symptom upper abdominal GSRS two symptom lower abdominal GSRS well total GSRS scores improved significantly RW0117 group compared placebo group Furthermore patient receiving RW0117 showed significant improvement GIS NDIK FDQoL score end treatment compared placebo group conclusion treatment RW0117 safe showed significant potential reducing FD symptoms",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40816579/",
        "source_type": "Global"
    },
    {
        "pmid": "40816116",
        "title": "Promoting sow-piglet information transfer and playful foraging by changes in pen design and feeding strategy to ease weaning: effects on pig performance and behaviour.",
        "abstract": "Strategies inspired natural behaviour pigs including learning sow playful foraging may alleviate behavioural problem weanling piglet enhance performance investigated effect family feeding system Fs dietary treatment providing family feeds Ff 2 × 2 design performance behaviour day 35 postweaning Sows n  104 piglet either kept Fs conventional system Cs fed either Ff Cf Fs sow could obtain feed throughout day provided plate accessible piglets Piglets sow could also jointly drink explore enrichment materials piglet feeder identical systems Fs contained enrichment material stimulate playful foraging Piglets weaned 27 day age Ff piglet feed offered postnatal day 2 day 9 postweaning contained artificial flavour several ingredient Ff sows diet allowing flavour transfer varying pellet size length increase texture diversity Fs piglet were apart piglet feed provided sow feed first 45 postweaning days Sow piglet performance body damage number eater postweaning behaviour diarrhoea determined Less Fs Cs sow shoulder lesions Fs proportion eaters preweaning piglet growth weaning weight higher day 9 postweaning Fs piglets feed intake higher growth lower possibly due higher incidence diarrhoea period BW day 35 postweaning unaffected system Ear tail damage body lesion score decreased Fs compared Cs piglet pre postweaning along ear tail biting behaviour postweaning Ff affect preweaning performance increased postweaning diarrhoea day 9 proportion piglet damaged ear day 9 tail biting frequency effect postweaning growth postweaning intake sows feed Fs piglet use ingredient sows diet Ff piglet diet might partly explain high incidence diarrhoea piglets thereby absence positive effect Fs Ff postweaning gain conclusion strategy based natural behaviour pig seem promising enhance piglet welfare around weaning adjustment postweaning nutritional need required",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40816116/",
        "source_type": "Global"
    },
    {
        "pmid": "40815944",
        "title": "Qu-yu-jie-du decoction maintenance therapy improves postoperative survival in metastatic colorectal cancer: a single-center randomized trial with 36-month follow-up.",
        "abstract": "Quyujiedu QYJD decoction established traditional Chinese medicine TCM formulation ten years empirical evidence support benefit colorectal cancer patients yet RCT validation postoperative maintenance therapy lacking Despite achieving evidence disease NED status curativeintent resection metastatic colorectal cancer mCRC 60  patient relapse within five years guidelinerecommended maintenance therapy determine whether QYJD decoction improves diseasefree survival DFS modulates inflammationlactate metabolism postoperative mCRCNED patients singlecenter randomized trial 140 stage IV mCRC patient achieving postresection NED status randomized ratio 11 either QYJD group 200 mLday 2 years control group routine followup Two patient per group withdrew consent prior intervention resulting intentiontotreat ITT population 136 patient 68 per group final analysis received standard adjuvant chemotherapy primary outcome DFS secondary outcome OS 123year survival rates adverse events inflammationlactate metabolism markers Compared control group QYJD decoction significantly improved DFS throughout observation period HR  0515 p  0004 1year DFS rate 912  6268 QYJD group versus 735  5068 control group p  001 2year DFS rate 569  4068 QYJD group versus 351  2568 control group p  0002 3year DFS rate 474  3268 QYJD group versus 324  2268 control group p  003 Significant difference observed across time point 1year 2year 3year DFS Regarding overall survival OS 2year OS rate 954  6568 QYJD group versus 851  5868 control group p  001 3year OS rate 687  4768 QYJD group versus 577  3968 control group HR  0407 p  0019 QYJD also significantly reduced inflammatory marker lactate dehydrogenase LDH p  005 common adverse event grade 1 hematologic toxicity anorexia diarrhea nausea generally mild manageable QYJD decoction significantly improves DFS show OS benefit postoperative mCRCNED patients also reduces systemic inflammationLDH term safety cause mild adverse events Chinese Clinical Trial Registry ChiCTR2100053521 registered November 24 2021",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815944/",
        "source_type": "Global"
    },
    {
        "pmid": "40815117",
        "title": "Safety and Efficacy of Givinostat for patients with Muscular dystrophy: A Systematic review.",
        "abstract": "Muscular dystrophyMD refers group genetic disorder leading progressive weakness degeneration skeletal muscle Among them Duchenne muscular dystrophyDMD Becker muscular dystrophyBMD common types Histone deacetylaseHDAC inhibitorsie Givinostat recently approved therapy DMD systematic review aim evaluate Givinostat MD patient regarding safety efficacy systematic review performed according PRISMA guideline searching Medline Embase Cochrane Library Web Science RCT comparing Givinostat v placebo therapy included primary outcome motor function alteration histopathologic muscle change secondary outcome adverse reactions total 188 record identified screening two clinical trial met inclusion criteria DMD patients Givinostat significantly slowed disease progression improving four stairclimb time p0037 reducing muscle fat infiltration BMD patients fibrosis progression significantly different p08282 MRI showed reduced muscle fat replacement Common adverse event included diarrhea thrombocytopenia hypertriglyceridemia leading dose reductions though new safety signal treatmentrelated death observed Givinostat seems effective slowing disease progression DMD little benefit BMD safety profile requires rigorous monitoring Efficacy difference might explained pathophysiology disease progression rate Larger longer followup trial warranted confirm longer term benefit optimize dosing strategies Givinostat offer potential diseasemodifying therapy DMD requires investigation establish role BMD",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815117/",
        "source_type": "Global"
    },
    {
        "pmid": "40814560",
        "title": "Efficacy and safety of EGFR-TKI for EGFR-mutated NSCLC: systematic review and network meta-analysis.",
        "abstract": "Afatinib Dacomitinib Osimertinib Aumolertinib Furmonertinib Gefitinib Erlotinib Icotinib shown work safe people epidermal growth factor receptor EGFRpositive nonsmall cell lung cancer NSCLC recent years difference efficacy safety lack comparative trial cause clinical confusion treatment selection study analyzes efficacy safety via network metaanalysis inform clinical decisions searched PubMed Embase Cochrane Library Web Science pertinent studies objective response rate ORR median progressionfree survival mPFS time treatment failure TTF median overall survival mOS adverse event AEs extracted efficacy analysis Afatinib greatest ORR SUCRA959 outperforming Gefitinib SUCRA227 Icotinib SUCRA307 Furmonertinib longest mPFS SUCRA926 outperforming Gefitinib SUCRA101 Afatinib SUCRA118 Dacomitinib best TTF SUCRA841 followed Afatinib Icotinib longer TTF Gefitinib SUCRA70 safety evaluations Aumolertinib performed best overall grade 15 AEs SUCRA300 highgrade ≥3 AEs safety SUCRA95 Afatinib worst overall safety rating SUCRA683 Osimertinib worst highgrade ≥3 AEs profile Afatinib Osimertinib showed significantly greater grade ≥3 AEs compared Furmonertinib Icotinib Gefitinib Aumolertinib reduced frequency rash diarrhea AfatinibDacomitinib increased risk vomiting network metaanalysis reveals firstline treatment thirdgeneration EGFRTKI Furmonertinib exceptional advantage mPFS safety suited patient longterm disease control needs Although secondgeneration Afatinib highest objective remission rate also increase possibility grade ≥3 AEs Clinically personalized program devised based patients mutation type tolerance factors headtohead trial required future validate finding optimize treatment techniques",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814560/",
        "source_type": "Global"
    },
    {
        "pmid": "40813488",
        "title": "Fecal gut microbiome alterations and its association with lactose intolerance in children with rotavirus infection-related diarrhea.",
        "abstract": "Rotavirus RV major cause childhood diarrhea damage intestinal epithelium may induce lactose intolerance patients Increasing study emphasized importance dysregulated gut microbiome community diseases study fecal sample rotavirusinfected child n  48 healthy control n  29 analyzed based 16S rRNA gene sequencing clinical data rotavirusinfected group stratified lactose tolerance status investigate distinctive feature gut microbial communities study verified shift gut microbiome constitution abundance feces healthy donor rotavirus infection children Notably Agathobacter Streptococcus Veillonella Roseburia significantly increased rotavirus infection patients relative abundance Ruminococcus gnavus group decreased Analyses alpha diversity unveiled significant difference abundance gut microbiota rotavirus infection patient without lactose intolerance particular abundance Parasutterella Lachnospiraceae NK4A136 group Morganella Veillonellaceae unclassified decreased significantly rotavirus infection patient lactose intolerance Further PLR inflammatory hematological ratio significantly elevated rotavirus infection patient lactose intolerance Overall study indicated characteristic change diversity taxonomy function gut microbiota rotavirus infection healthy control children revealing existence dysbiosis rotavirus infection Further analysis identified compositional uniqueness gut microbiota rotavirus infection patient without lactose intolerance highlighting diversity taxonomy gut microbiome association inflammatory state • Rotavirus causing diarrhea child worldwide causing damage intestinal epithelium lactose intolerancerelated diarrhea children • Results demonstrated characteristic change gut microbiome rotavirusinfected child investigated different gut microbiome composition rotavirus infectionrelated lactose intolerance lactose tolerance patients • Further relationship gut microbiome inflammatory hematological ratio explored",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813488/",
        "source_type": "Global"
    },
    {
        "pmid": "40813226",
        "title": "New Onset Systemic Lupus Erythematous After Kidney Transplant: Case Report.",
        "abstract": "diagnosis new onset autoimmune disease kidney transplant patient challenging new onset SLE kidney transplant rare condition case reported describe case kidney transplant patient who 9 year presented intermittent fever diarrhea inflammatory migratory polyarthralgia myalgias cramp erythematous rash cleavage area Immunological testing revealed positive antinuclear antibody ANA 1640 antidoublestranded DNA antibody 532 IUmL elevated beta2 microglobulin 10559 UmL leading diagnosis de novo SLE according EULARACR 2019 criteria Notably patient exhibited evidence renal involvement onset stable kidney function normal urinary sediment throughout followup Ten month undergoing treatment corticosteroid belimumab partial clinical serological improvement case highlight rare presentation posttransplant SLE without renal involvement reinforcing need high index suspicion transplant recipient presenting nonspecific inflammatory symptoms",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813226/",
        "source_type": "Global"
    },
    {
        "pmid": "40813099",
        "title": "From poverty to health: intraurban inequalities in child health indicators in low-income and middle-income countries during the SDG era.",
        "abstract": "Urban area generally associated better health outcomes However many lowincome middleincome country LMICs rapid urbanisation led significant health disparities inequalities especially affecting urban poor often overlooked study focused solely ruralurban differences study aimed assess overall countryspecific intraurban inequality under5 neonatal mortality rates immunisation coverage careseeking acute respiratory infection ARIs coverage diarrhoea treatment stunting wasting overweight child 5 Demographic Health Survey datasets collected since 2015 48 LMICs analysed constructed urban poor cluster using United Nations Human Settlements Programme definition slum categorised urban poor urban nonpoor clusters Wagstaff normalised concentration index WCI concentration curve used assess urban povertyrelated inequality child health indicators LMICs 137 95 CI 136 139 urban child lived poor clusters 65 urban cluster classified poor Chad Ethiopia Afghanistan child health indicators except neonatal mortality exhibited significant inequality urban poor nonpoor Despite inconsistency across countries prourban poor inequality under5 mortality WCI0069 stunting WCI0121 wasting WCI0088 Full vaccination coverage WCI0078 overweight WCI0087 careseeking child acute respiratory infection WCI0131 receiving oral rehydration salt zinc diarrhoea WCI0127 showed prourban nonpoor inequality LMICs Substantial intraurban inequality observed child health indicators Under5 mortality stunting wasting concentrated among urban poor children health service utilisation overweight concentrated among urban nonpoor children Improving access clean water sanitation quality healthcare education underserved urban areas along combating urban poverty promoting healthy lifestyles essential achieving better health outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813099/",
        "source_type": "Global"
    },
    {
        "pmid": "40811904",
        "title": "Roridin E and satratoxin H, macrocyclic trichothecene mycotoxins, induce endoplasmic reticulum stress-dependent apoptosis through ribosome interaction in B16 mouse melanoma cells.",
        "abstract": "Podostroma cornudamae commonly known red deers horn mushroom highly toxic specie responsible severe poisoning characterized vomiting diarrhea dehydration impaired consciousness potentially death mushroom notorious content macrocyclic trichothecene mycotoxins ongoing research aimed discovering bioactive natural compounds isolated thirteen macrocyclic trichothecene mycotoxin P1P13 methanol extract plate culture P cornudamae chemical structure mycotoxin elucidated analysis nuclear magnetic resonance NMR spectroscopy highresolution electrospray ionization mass spectrometry HRESIMS macrocyclic trichothecene mycotoxin previously reported exhibit antifungal antiviral anticancer activities antimelanoma effect documented date study examined cytotoxicity isolated mycotoxin P1P13 mouse melanoma B16F10 cell explored underlying molecular mechanisms Among isolated compounds P1 roridin E P5 satratoxin H exhibited substantial cytotoxicity demonstrated dosedependent inhibition cell proliferation increased expression level cleaved caspase3 Bax elevated intracellular reactive oxygen specie ROS Importantly cytotoxic effect elicited roridin E satratoxin H significantly attenuated following scavenging ROS glutathione GSH Additionally molecular docking analysis indicated high binding affinity roridin E satratoxin H toward ribosomal targets Treatment two mycotoxin led increased expression critical endoplasmic reticulum ER stress biomarkers activation unfolded protein response UPR signaling pathway involving activating transcription factor 6 ATF6 protein kinase RNAlike endoplasmic reticulum kinase PERK inositolrequiring enzyme 1 IRE1 Collectively finding suggest roridin E satratoxin H induce ER stressmediated caspasedependent apoptosis melanoma cells result highlight potential macrocyclic trichothecene mycotoxin promising therapeutic candidate melanoma treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40811904/",
        "source_type": "Global"
    },
    {
        "pmid": "40810941",
        "title": "Prevalence and Treatment of Diarrhea Among Children in India, 2016-2021.",
        "abstract": "World Health Organization recommends use oral rehydration solution ORS treatment child diarrhea India adherence guideline remains far less complete elucidate geographic variation ORS treatment child diarrhea within Indias 720 districts repeated crosssectional study used data 2 round Indias National Family Health Survey 2016 2021 Complete diarrhea data available 246 695 child 2016 223 785 child 2021 720 district waves Data ORS treatment available 22 413 child 2016 15 302 child 2021 child lived 716 Indias 720 district 2016 718 district 2021 data analyzed October 2024 primary outcome districtlevel percentage child received ORS treatment diarrhea past 2 weeks prevalence diarrhea also estimated value estimated outcome 2016 2021 change time could estimated SD communitylevel prevalence child received ORS treatment district measure withindistrict inequality also estimated 2016 2021 study included 246 695 child younger 5 year mean SD age 20 14 years 128 098 boy 118 597 girls diarrhea prevalence 22 413 child younger 5 year mean SD age 15 13 years 12 050 boy 10 363 girls ORS treatment 2016 study also included 223 785 child younger 5 year mean SD age 20 14 years 115 632 boy 108 153 girls diarrhea prevalence 15 302 child younger 5 year mean SD age 16 14 years 8160 boy 7142 girls ORS treatment 2021 92 95 CI 9193 child diarrhea 2 week prior survey 2016 506 95 CI 500513 treated ORS 2021 73 95 CI 7274 child diarrhea 607 95 CI 599615 treated ORS considerable betweendistrict variation prevalence ORS treatment child diarrhea as 2021 state Union Territory lowest districtlevel prevalence ORS treatment Haryana 490 state Union Territory highest districtlevel prevalence ORS treatment Jammu Kashmir 834 prevalence ORS treatment decreased 249 percentage point 185 district 2016 2021 even though nationally prevalence ORS treatment increased period median 575 IQR 472665 median 624 IQR 569725 Finally many district high prevalence child diarrhea low prevalence ORS treatment 71 districts prevalence child diarrhea increased prevalence ORS treatment decreased 2016 2021 crosssectional study prevalence child diarrhea treatment ORS India found prevalence ORS treatment child diarrhea increased national level 2016 2021 increase even within Indias 720 districts finding suggest effort aimed promoting ORS treatment child diarrhea India must address placebased factor might associated underuse treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810941/",
        "source_type": "Global"
    },
    {
        "pmid": "40810318",
        "title": "Is budesonide on demand an option for microscopic colitis treatment? A qualitative study on patient's perspective.",
        "abstract": "Budesonide standard treatment microscopic colitis MC effectively alleviating diarrhoea However diarrhoea recurrence upon discontinuation raise idea feasibility ondemand treatment selfmanagement emphasized care chronic diseases less known patients perspective initiating budesonide ondemand qualitative study conducted using semistructured interview 15 patient diagnosed MC previous experience budesonide treatment Data analysed using qualitative content analysis explore patients perception ondemand treatment Three main category emerged 1 bSelfmanagement confidence handling flaresb Patients expressed strong desire selfmanagement valuing ability initiate treatment independently flares However hesitant due uncertainty proper dosing treatment duration 2 bPerceptions budesonide attitude towards medicationb budesonide perceived highly effective concern longterm use side effects potential loss efficacy influenced adherence adjusted dos based diarrhoea others preferred guidance physician initiating treatment 3 bThe role healthcare treatment decisionsb Patients emphasized importance accessible healthcare clear treatment guidelines structured followup Many felt healthcare provider focused primarily prescribing medication rather providing holistic approach model integrating personcentred care professional guidance seen ideal optimizing treatment outcomes Ondemand budesonide treatment could provide patient greater flexibility requires individualized support structured approach balance selfmanagement followup personcentred guidance may enhance adherence improve quality life patient MC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810318/",
        "source_type": "Global"
    },
    {
        "pmid": "40810084",
        "title": "Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis.",
        "abstract": "Immune checkpoint inhibitor ICIs cause severe gastrointestinal immunerelated adverse event irAEs often leading treatment interruption increased morbidity Immunemediated colitis IMC range mild diarrhea lifethreatening colitis sometimes requiring urgent intervention corticosteroid firstline treatment selective immunosuppressive therapy SIT either infliximab vedolizumab used steroidrefractory dependent cases However standardized practice lacking treatment decision largely left provider discretion study compare infliximab vedolizumab IMC focusing remission rates recurrence SIT dosing systemic steroid exposure duration identified six retrospective cohort study compared infliximab vedolizumab treatment IMC systematic search PubMed EMBASE Cochrane Library Scopus CINAHL Google Scholar Web Science English inception October 2024 identified literature extracted pertinent data remission recurrence IMC Pooled analysis heterogeneity analysis performed using R Studio version 441 risk bias assessed using NewcastleOttawa Scale total six study 645 patient included ICIassociated colitis vedolizumab associated lower recurrence rate odds ratio OR 029 95 confidence interval CI 015  054 shorter systemic steroid exposure mean difference MD 1688 days 95 CI 2047 1330 compared infliximab vedolizumab showed improved remission statistically significant difference remission rate vedolizumab infliximab monotherapy OR 316 95 CI 029  3401 Remission achieved fewer dos infliximab vedolizumab MD 116 95 CI 009  222 mean number vedolizumab dos 257 raw mean score MRAW 257 95 CI 143  271 mean number infliximab dos 136 MRAW 136 95 CI 069  202 Among patient ICIinduced colitis vedolizumab demonstrated superiority infliximab associated lower rate colitis recurrence decreased systemic steroid exposure although required higher number dos compared infliximab",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810084/",
        "source_type": "Global"
    },
    {
        "pmid": "40809648",
        "title": "Adult Measles Outbreak in New Jersey: The Dangers of Declining Vaccination Rates.",
        "abstract": "case highlight rare presentation measles unvaccinated adult male New Jersey emphasizing risk posed declining vaccination rates outbreak linked case illustrates public health danger vaccine hesitancy insufficient immunization coverage 32yearold male presented five day worsening fever nausea vomiting diarrhea spreading maculopapular rash Physical examination revealed petechial lesion soft palate lacypatterned rash tachycardia Laboratory finding included thrombocytopenia electrolyte imbalances hyperglycemia elevated liver enzymes Serologic testing confirmed diagnosis measles patient received supportive care delay isolation protocol resulted secondary transmission four unvaccinated contacts including three child one adult Public health authority alerted outbreak containment measure implemented case underscore critical role vaccination preventing measles outbreak need proactive public health strategy address vaccine hesitancy serf reminder consequence declining vaccination rate importance maintaining herd immunity protect vulnerable populations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40809648/",
        "source_type": "Global"
    },
    {
        "pmid": "40809193",
        "title": "The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.",
        "abstract": "antiapoptotic protein myeloid cell leukemia 1 Mcl1 promotes cell survival acute myeloid leukemia AML overexpression associated resistance venetoclax Voruciclib oral cyclindependent kinase 9 inhibitor indirectly decrease Mcl1 protein expression synergistic activity venetoclax AML preclinical models hypothesized voruciclib combination venetoclax would induce response patient AML disease progression venetoclax therapy doseescalation study evaluated voruciclib administered day 1 14 28day cycle venetoclax daily study enrolled 41 adult patient AML failure previous standard therapies Patients median 2 range 17 previous line therapy 19 patient 46 ≥3 previous line therapy 39 95 previous venetoclax doselimiting toxicity reported 7 dose level evaluated common adverse event nausea 34 febrile neutropenia 32 diarrhea 22 dyspnea 22 hypokalemia 22 thrombocytopenia 22 Antileukemic activity observed 10 24 patients including 3 complete marrow remission 7 stable disease lasting ≥3 months observed rebound circulating blast 14 day singleagent venetoclax dosing 40 evaluable patients Mcl1 protein expression RNA polymerase II Ser2 phosphorylation decreased voruciclib Overall combination voruciclib venetoclax tolerable patient relapsedrefractory AML antileukemic activity showed ontarget effect heavily pretreated patient disease progression venetoclax trial registered wwwClinicalTrialsgov NCT03547115",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40809193/",
        "source_type": "Global"
    },
    {
        "pmid": "40807514",
        "title": "Impact of Chitooligosaccharide Conjugated Epigallocatechin Gallate and Non-Thermal High-Voltage Atmospheric Cold Plasma on <i>Vibrio parahaemolyticus</i>: An In Vitro Study and the Use in Blood Clam Meat.",
        "abstract": "iVibrio parahaemolyticusi leading cause bacterial diarrhea human shellfish consumption Thailand blood clam popular shellfish homemade cooking often result insufficient heating Therefore consumer may suffer food poisoning due iVibrioi infection study aimed determine effect chitooligosaccharide conjugated epigallocatechin gallate COSEGCG different concentration 200 400 ppm combined highvoltage atmospheric cold plasma HVACP inhibiting iV parahaemolyticusi vitro challenged blood clam meat Firstly HVACP condition optimized gas composition treatment time 20 60 s 70 Ar 30 Osub2sub gas mixture resulted highest ozone formation treatment time 60 used study COSEGCG conjugate 400 ppm HVACP ACPCE400 completely killed iV parahaemolyticusi incubation 37 °C 6 h Furthermore antibacterial ability ACPCE400 treatment bacterial cell advocated due increased cell membrane damage permeability leakage protein nucleic acids Scanning electron microscopy SEM showed cell elongation pore formation confocal microscopy revealed disrupted biofilm formation Additionally shelf life challenged blood clam meat treated ACPCE400 extended nine days SEM analysis revealed damaged bacterial cell meat surface ACPCE400 treatment indicating antibacterial activity combined treatment Thus HVACP combined COSEGCG conjugate especially highest concentration 400 ppm effectively inhibited microbial growth extended shelf life contaminated blood clam meat",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40807514/",
        "source_type": "Global"
    },
    {
        "pmid": "40807050",
        "title": "Constipation in Ulcerative Colitis: An Underestimated Problem.",
        "abstract": "Ulcerative colitis chronic intestinal disorder belongs category inflammatory bowel diseases usually characterized presence bloody diarrhea abdominal pain due accelerated transit intestinal sensibilization following inflammation colonic mucosa However literature report ulcerative colitis may sometimes feature fecal stasis constipation apparent paradox may partially explained motor abnormality large bowel following inflammation damage enteric innervation onset parietal fibrosis time Moreover anorectal abnormality pelvic floor dyssynergia may explain symptom constipation reported subset patients Since abnormality may responsible diagnostic delay non partial response therapy important recognize early possible avoid incorrect clinical therapeutic approach patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40807050/",
        "source_type": "Global"
    },
    {
        "pmid": "40805239",
        "title": "Real-World Toxicity and Effectiveness Study of Abemaciclib in Greek Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Multi-Institutional Study.",
        "abstract": "study aimed assess realworld toxicity efficacy data patient early advanced breast cancer BC received treatment abemaciclib prospectiveretrospective multiinstitutional collection clinicopathological toxicity outcome data patient early metastatic hormone receptor HRpositive human epidermal growth factor receptor 2 HER2negative BC received treatment abemaciclib combination endocrine therapy department oncology Greece Treatment combination abemaciclib endocrine therapy accepted primary end point toxicity rate patient study June2021 May2024 245 woman received abemaciclibendocrine combination therapy median age 57 years these 169 69 received abemaciclib adjuvant therapy earlystage disease 76 31 treated advanced BC time data cutoff 133 847 patient remained 2year treatment period common adverse event AE diarrhea 51 primarily Grade ≤ 2 Dose modification due AEs required 192 cases treatment discontinuation occurred 51 difference dose modificationdiscontinuation rate older patient 65 years remaining patients earlystage BC patients 2year DFS OS rate 908 100 respectively patient advanced cancer 70 308 1year PFS OS rate 78 963 respectively study confirms safety effectiveness abemaciclib alignment registrational trial offering valuable insight toxicity management clinical outcome routine practice without identifying new safety concerns ClinicalTrialsgov NCT04985058",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805239/",
        "source_type": "Global"
    },
    {
        "pmid": "40805202",
        "title": "Surgical, Histopathological, and Quality of Life Outcomes Following Neoadjuvant Chemotherapy and Pancreatectomy for Borderline Resectable and Locally Advanced Pancreatic Cancer.",
        "abstract": "bBackgroundObjectivesb Treatment borderline resectable BRPC locally advanced LAPC pancreatic cancer involves neoadjuvant chemotherapy followed complex surgery posing significant risk toxicity complications change quality life QoL study aim investigate impact neoadjuvant chemotherapy followed resection overall survival OS QoL bMethodsb Consecutive patient BRPC LAPC included populationbased study NORPACT2 January 2018 December 2020 reviewed bResultsb total 54 patient BRPC n  43 LAPC n  11 underwent neoadjuvant chemotherapy followed pancreatectomy majority 667 received mFOLFIRINOX Fortysix 852 patient underwent pancreatoduodenectomy Vascular resection performed 32 593 patients Fourteen 259 patient experienced major complications majority resected specimen demonstrated T2 63 N 796 R1 852 status Median OS 31 CI 247373 months multivariate analysis CAP 3 ipi  0035 predicted worse survival Forty 741 patient experienced recurrence Global QoL ipi  0031 social role functioning ipi  0024 ipi  0031 improved three month surgery Pain ipi  0042 dyspnea ipi  0004 appetite loss ipi  0028 diarrhea ipi  0007 improved postresection bConclusionsb Patients BRPC LAPC undergoing neoadjuvant chemotherapy resection survival comparable primary resectable pancreatic cancer Postoperative morbidity acceptable QoL recovered postsurgery CAP grade independent negative prognostic factor",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805202/",
        "source_type": "Global"
    },
    {
        "pmid": "40805136",
        "title": "Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15).",
        "abstract": "Studies suggested synergism lenalidomide LEN ibrutinib IBR multiple myeloma MM downregulate IRF4 key target master transcriptional factor regulating myeloma cell survival 3  3 phase trial conducted determine maximum tolerated dose MTD IBR combination LEN  dexamethasone DEX patient relapsedrefractory RR MM least one prior line therapy Three dose level DLs planned cycle length 28 days IBR administered orally daily dos 560 mg DL12 840 mg DL3 LEN administered orally day 121 dos 15 mg DL1 25 mg DL23 DEX administered orally day 1 8 15 22 dose 40 mg age  75 year dose 20 mg ≥75 year DL13 Patients glomerular filtration rate GFR 60 ≥30 mLmin treated accordance manufacturers instruction LEN 10 mg Doselimiting toxicity DLTs included following grade 4 neutropenia lasting 5 days thrombocytopenia febrile neutropenia nausea vomiting diarrhea grade 3 thrombocytopenia bleeding platelet transfusion grade 34 hyperglycemia thromboticembolic event nonhematologic toxicities overall response rate ORR defined percentage patient partial response PR good partial response VGPR complete response CR according IMWG criterion two consecutive evaluation least 4 week apart clinical benefit rate CBR defined percentage patient stable disease SD better outcome two consecutive evaluation week apart Fourteen patient DL1 six patients DL2 three patients DL3 five patients registered study March 2019 May 2023 prior closure due limited accrual Thirteen patient included summary toxicity response one patient DL3 halted participation prior start treatment Two patient DL3 excluded determination MTD one discontinued cycle 1 treatment due COVID19 infection another mistakenly taken 280 mgday IBR instead assigned 840 mgday dose cycle 1 one patient developed DLT DL1 grade 3 nonviral hepatitis median number cycle administered 4 range 156 Severe toxicity reported included grade 4 lymphocytopenia 1 grade 4 thrombocytopenia 1 grade 5 sepsis setting PD 1 Disease response included VGPR DL1 CR DL3 Thus ORR 154 90 CI 28410 One patient DL1 maintained SD 46 year discontinuing treatment undergo alternative therapy Another five patient maintained SD ≥ 2 consecutive cycles Thus CBR 615 90 CI 355834 combination LEN IBR RR MM proved feasible manageable toxicity majority discontinuation due disease progression",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805136/",
        "source_type": "Global"
    },
    {
        "pmid": "40804690",
        "title": "Efficacy of Credelio Quattro<sup>™</sup> (lotilaner, moxidectin, pyrantel, praziquantel) and Credelio<sup>™</sup> (lotilaner) against longhorned tick, Haemaphysalis longicornis,-induced infestations on dogs.",
        "abstract": "Haemaphysalis longicornis longhorned tick invasive tick specie identified increasing number region across USA tick specie competent vector various pathogen dogs humans species heavy infestation documented lead exsanguination Therefore determination ectoparasiticides providing adequate treatment control H longicornis imperative help reduce vectorborne disease transmission protect infestation dogs Three laboratory study conducted evaluate efficacy Credelio Quattro Credelio treatment control H longicornis total 30 dog per study randomized receive either placebo Credelio Quattro Credelio Day 0 according complete block design basis pretreatment live attached H longicornis counts infested Day 7 assess efficacy preexisting infestations enrolled dog infested 50 unfed adult H longicornis Day 2 1 prior treatment Residual efficacy posttreatment evaluated subsequent infestation Days 5 12 19 30 tick collected evaluated live dead free attached 48 h treatment infestation Adequacy infestation achieved least two study every infestation time point evaluated Credelio Quattro Credelio provided 100 efficacy H longicornis Day 2 Day 32 live tick observed dogs statistically significant number dead tick recovered treated group compared control assessment days Posttreatment treatmentrelated diarrhea reported six dog receiving Credelio Quattro one dog receiving Credelio Day 0 dog recovering Day 1 laboratory study described confirm safety effectiveness single dose Credelio Quattro Credelio minimum effective dosage 20 mgkg lotilaner 002 mgkg moxidectin 5 mgkg praziquantel 5 mgkg pyrantel 20 mgkg lotilaner respectively treatment control H longicornis infestation dog one month",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40804690/",
        "source_type": "Global"
    },
    {
        "pmid": "40804463",
        "title": "Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.",
        "abstract": "Overweight obesity major global health issues increasing disease risk straining healthcare systems Glucagonlike peptide1 receptor agonist GLP1 RAs effective weight loss cause gastrointestinal side effects affecting adherence Research often focus diabetics leaving gap understanding effect nondiabetic individual overweight obesity systematic review doseresponse network metaanalysis address gap analyzing gastrointestinal adverse event GLP1 RAs nondiabetic subject overweight obesity evaluated available evidence searching PubMed EMBASE databases according specific inclusion exclusion eligibility criterion evaluate gastrointestinal adverse event associated GLP1 RAs nondiabetic individual overweight obesity Quality assessment included study conducted using Cochrane Collaborations tool Thirtynine article included review showing total number 33354 individuals Nausea vomiting diarrhea constipation common gastrointestinal adverse effects evaluated GLP1 RAs led significant increase nausea risk orforglipron showing highest risk followed exenatide tirzepatide semaglutide liraglutide Additionally liraglutide orforglipron semaglutide tirzepatide associated increased vomiting risk cagrilinitide exenatide showed significant increase Exenatide cagrilinitide orforglipron associated diarrhea risk Finally semaglutide liraglutide associated increased constipation risk cagrilinitide exenatide showed significant increase GLP1 RAs showed several adverse gastrointestinal effect nondiabetic patient overweight obesity Understanding different risk profile GLP1 RAs help clinician make informed treatment decision balancing therapeutic benefit potential side effects",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40804463/",
        "source_type": "Global"
    },
    {
        "pmid": "40803807",
        "title": "Perceptions and interventions concerning coccidiosis in Dutch sheep farms.",
        "abstract": "Coccidiosis sheep protozoan disease young lamb yet fully understood control still largely relies use coccidiostats despite development resistance hypothesized Netherlands proper diagnosis always made treatment initiated possibly leading overuse coccidiostats aim study investigate perception intervention Dutch sheep farmer veterinarian regarding coccidiosis special attention treatment use anticoccidial drugs online survey completed 114 sheep farmer 57 veterinary practitioners surveyed sheep farmer appeared genuinely interested coccidiosis threequarters considering important problem flock Seventy per cent sheep farmer 84  veterinarian reported diarrhoea important symptom coccidiosis Almost threequarters sheep farmer conducted faecal examination two preceding years 87  per cent performed treatments half used coccidiostats annually wide variety treatment approaches Standard treatment lamb without clinical indication 4 week age treatment adult sheep reported 26  13  13  responding farmers respectively latter two considered incorrect treatments contrast veterinarian estimated that average coccidiostats prescribed 30  sheep farm practice treatment primarily based clinical sign faecal examination results Potential obstacle correct diagnosis included practical difficulty collecting faecal samples additional costs Remarkably questionable treatment common including treatment without history coccidiosis treatment lamb younger one month age treatment adult sheep Although correct dosage coccidiostats crucial 43  veterinarian advised dosing based heaviest animals case weight visually estimated farmer veterinarian Unfortunately treatment frequently applied without proper diagnosis applied dosage often correct may lead unnecessary incorrect use coccidiostats resulting increased risk resistance development Since veterinarian regarded important advisors play key role solution supporting veterinarians preventive measure prudent use coccidiostats promoted",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803807/",
        "source_type": "Global"
    },
    {
        "pmid": "40802670",
        "title": "Pediatric Graves' disease: insights into clinical characteristics and treatment outcomes.",
        "abstract": "identify early manifestation Graves disease young patient treatment outcomes hospitalbased review case record 47 child aged 1 month 18 years Graves disease 2011 2022 Data summarized statistically analyzed study included 47 patient Graves disease 31 66 girls average age initial diagnosis 1279 ± 375 years Common presenting complaint included heat intolerance 766 excessive sweating 745 palpitation 681 tremor 489 weight loss 383 increased appetite 34 diarrhea 319 constipation 43 mean thyrotropin receptor antibody titer 1693 ± 1347 IUL Remission achieved two 43 patient treated antithyroid drugs Graves disease common cause juvenile hyperthyroidism treating physician aware sign symptom avoid treatment delays",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802670/",
        "source_type": "Global"
    },
    {
        "pmid": "40802252",
        "title": "Management of diarrhea in solid organ transplantation.",
        "abstract": "Diarrhea common complaint solid organ transplant recipients review infectious noninfectious cause diarrhea management Diagnostics diarrhea commonly incorporated multiplex gastrointestinal panel provide rapid testing identification pathogens rate Clostridium difficile transplant population increased fidaxomicin recommended therapy choice first episode recurrence available Oral vancomycin remains alternative Norovirus important rule case chronic diarrhea Nitazoxanide shown mixed result used norovirus therapy SARSCoV2 despite respiratory virus infect gut epithelium present diarrhea Noninfectious cause especially mycophenolaterelated well inflammatory bowel disease differential especially infectious cause identified detailed history diagnostics including molecular testing endoscopy targeted therapy infectious cause mainstay management diarrhea transplant recipient",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802252/",
        "source_type": "Global"
    },
    {
        "pmid": "40801049",
        "title": "Fufang Taizishen Granules Attenuate Chemotherapy-Induced Intestinal Mucositis by Modulating Gut Microbiota and Amino Acid Metabolism.",
        "abstract": "Chemotherapyinduced intestinal mucositis severe adverse effect affecting cancer patients currently effective strategy prevention Fufang Taizishen granule FFTZS traditional Chinese medicine TCM known antiinflammatory antifatigue immunostimulatory properties shown therapeutic potential However effect FFTZS chemotherapyinduced intestinal mucositis underlying mechanism remain unclear mouse model intestinal mucositis induced using 5FU irinotecan assess protective effect FFTZS study found FFTZS enhanced food intake reduced diarrhea index improved histopathological damage colonic tissues FFTZS also reduced inflammatory cell infiltration inhibited apoptosis Moreover FFTZS treatment increased expression Claudin1 ZO1 proteins Microbial analysis revealed enrichment beneficial bacteria reduction opportunistic pathogens whereas metabolomic analysis showed FFTZS corrected amino acid metabolic disturbance induced chemotherapy finding suggest FFTZS mitigates chemotherapyinduced intestinal mucositis preserving mucosal integrity modulating gut microbiota restoring metabolic homeostasis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40801049/",
        "source_type": "Global"
    },
    {
        "pmid": "40799553",
        "title": "Identification of natural products and synthetic analogs which inhibit microsporidia spores and prevent infection.",
        "abstract": "Microsporidiosis disease caused microsporidia affect many animals symptom ranging diarrhea death especially immunocompromised individuals Current treatments albendazole fumagillin limited efficacy address problem utilized iCaenorhabditis elegansi infected natural microsporidian iNematocida parisiii evaluate 4080 structurally diverse compound Boston University Center Molecular Discovery BUCMD chemical library screen identified 34 compound effectively inhibited iN parisiii infection restored reproductive capacity iC elegansi  17 compound validated prevented iN parisiii infection iC elegansi  10 capable suppressing microsporidia invasion inactivating mature spores Additionally five identified compound also effective iPancytospora epiphagai  specie related human ii infecting microsporidia Together work identifies characterizes compound inhibit microsporidia infection Microsporidia large group microbial parasite infect many animals including humans Many agriculturally important animal honey bees shrimp crabs fish infected microsporidia infection often result smaller animals fewer offspring death two drug commonly used treat microsporidia infections due specie resistant host toxicity need identify microsporidia inhibitors study screened 4000 small molecule using model round worm infected microsporidia identified several dozen inhibitor characterized compound prevented infection determining stage parasite act upon Together work identified characterized compound could used starting point design better microsporidia inhibitors",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799553/",
        "source_type": "Global"
    },
    {
        "pmid": "40797386",
        "title": "Safety evaluation of tucatinib: Adverse event signal mining and analysis based on the FAERS database.",
        "abstract": "purpose study evaluate adverse event AEs associated tucatinib mining data US Food Drug Administration Adverse Event Reporting System FAERS explore potential drugrelated AEs thereby guiding safe clinical use extracted AE report involving tucatinib FAERS database spanning 1st quarter 2020 4th quarter 2024 report categorized based preferred term system organ classes risk signal subsequently grouped analysis Among 12225 AEs listing tucatinib primary suspected drug total 103 preferred term AEs identified across 22 different system organ classes reports proportion female higher male 9702 v 126 highest number AEs reported 45 59 year 1529 median interquartile range time AE onset 3000 day 80010400 AEs occurred mainly within 1st month n  152 2616 60 day drug administration n  106 1824 Among numerous positive risk signals diarrhea nausea vomiting stomatitis rash palmarplantar erythrodysesthesia syndrome hepatotoxicity anemia peripheral neuropathy exhibited high signal strength largely aligned current prescribing information addition AEs explicitly mentioned package insert also observed included platelet count abnormal ejection fraction decreased aortic valve incompetence dehydration hypokalemia various nail skinrelated problem eg fingerprint loss ingrowing nail onychalgia onychomadesis skin discolorationhypertrophyhyperpigmentationexfoliation pigmentation disorder blister etc well nervous system disorder eg memory impairment brain edema central nervous system lesion hyperesthesia taste disorder emotional disorder paronychia also risk various AEs treatment tucatinib clinical application essential monitor closely dermatologicnail conditions gastrointestinal issues cardiovascular abnormalities neuropsychiatric manifestations adverse event occur disease progression observed timely intervention necessary prevent severe organ damage disease deterioration",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40797386/",
        "source_type": "Global"
    },
    {
        "pmid": "40797385",
        "title": "Investigation of lung transplant recipients' medical treatment compliance and gastrointestinal symptoms in the long term: A cross-sectional study.",
        "abstract": "study aim examine lung transplant recipients adherence drug regimen gastrointestinal disorder suffered sample descriptive crosssectional research comprised 58 lung transplant recipient discharged hospital data collection process used sociodemographic healthrelated characteristic information form immunosuppressant therapy adherence scale Morisky medication adherence scale gastrointestinal symptom rating scale data analysis utilized descriptive statistical methods Mann Whitney U Spearman correlation mean age lung transplant recipient 4437 ± 918 years participant lung transplant recipients 534 female 655 struggling comorbidities 517 underwent lung transplantation 5 year ago 172 oxygendependent 517 coughs 31 dyspnea 293 hypertension lung transplant recipient using corticosteroid 914 using tacrolimus found statistically significant connection use mycophenolate mofetil constipation use tacrolimus diarrhea use amlodipine gastroesophageal reflux lung transplant recipients Lung transplant recipients adherence immunosuppressant medication average medication used associated gastrointestinal symptoms finding study highlight lung transplant recipients inhome care treatment need continue",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40797385/",
        "source_type": "Global"
    },
    {
        "pmid": "40797223",
        "title": "PEDV infection downregulates goblet cell differentiation through activating the Notch pathway.",
        "abstract": "Porcine epidemic diarrhoea virus PEDV widespread porcine coronavirus worldwide causing high mortality high incidence rate among piglets molecular mechanism PEDV regulates epithelial cell function differentiation well disruption intestinal mucosal barrier yet fully understood study reveals PEDV infection reduces number goblet cell impairs intestinal barrier integrity newborn piglets Regarding pathway involved differentiation intestinal stem cell ISCs PEDV infection concurrently activates Notch MAPK pathway suppressing Wntβcatenin pathway intestine piglets Furthermore vitro experiment using intestinal monolayer organoid model showed PEDV infection hinders goblet cell differentiation activating Notch signalling pathway Additionally PEDVencoded ORF3 protein crucial activating Notch pathway inhibits goblet cell differentiation PEDVinfected intestinal monolayer organoids study offer new insight mechanism underlying intestinal mucosal barrier dysfunction induced PEDV infection",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40797223/",
        "source_type": "Global"
    },
    {
        "pmid": "40792315",
        "title": "Gallstone Ileus as an Uncommon Etiology of Intestinal Obstruction: A Case Report.",
        "abstract": "Although gallstone commonly confined biliary system rare instances may migrate intestinal tract cause obstruction scenario often observed older adult history gallbladder pathology describe case 46yearold woman developed small bowel obstruction secondary large impacted gallstone despite prior biliary disease clinical presentation included 15day history abdominal pain bilious vomiting diarrhea Laboratory test revealed leukocytosis acute kidney injury Contrastenhanced computed tomography demonstrated pneumobilia small bowel obstruction radiopaque ectopic gallstone Exploratory laparotomy confirmed 4 × 3 × 4 cm gallstone impacted 30 cm proximal ileocecal valve successfully extracted via longitudinal enterotomy postoperative recovery uneventful case illustrates diagnostic surgical challenge posed gallstone ileus emphasizes importance considering condition even patient without prior biliary pathology Enterolithotomy proved safe effective treatment setting",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40792315/",
        "source_type": "Global"
    },
    {
        "pmid": "40792279",
        "title": "Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database.",
        "abstract": "Pacritinib selective Janus kinase JAK inhibitor approved treatment myelofibrosis adult severe thrombocytopenia However safety profile realworld population remains unclear aim study provided comprehensive profile pacritinibs safety evaluating adverse event AEs using realworld pharmacovigilance database Data FDA Adverse Event Reporting System FAERS database spanning first quarter 2022 second quarter 2024 served basis analysis identify potential AE risk signals several disproportionality analysis method applied including reporting odds ratio proportional reporting ratio multiitem gamma Poisson shrinker Bayesian confidence propagation neural network total 4304335 AE report collected FAERS 1940 report identifying pacritinib primary suspect drug Significant disproportionality observed following system organ classes gastrointestinal disorders investigations surgical medical procedures Common preferred term identified including diarrhea fatigue death nausea platelet count decreased hemoglobin decreased Notably 26 offlabel AEs also identified study would provide valuable insight postmarketing safety surveillance assessment pacritinib guide clinical practice",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40792279/",
        "source_type": "Global"
    },
    {
        "pmid": "40792054",
        "title": "Yeast peptides alleviate diarrhea in neonatal lambs by enhancing the colonic barrier function and modulating colonic microbiota.",
        "abstract": "underdeveloped intestinal tissue immature microbiota neonatal lamb predispose frequent diarrhea even death expanding breeding losses Yeast peptide enzymatic product yeast strains recognized antimicrobial peptide due demonstrated antimicrobial properties study aimed investigate impact yeast peptide supplementation incidence diarrhea neonatal lambs well underlying regulatory mechanism involved Thirtytwo onedayold lamb randomly allocated four treatments CON YP500 YP1000 YP2000 receiving 0 mgd 500 mgd 1000 mgd 2000 mgd yeast peptides respectively dietary supplementation yeast peptide elicited significant reduction fecal score incidence diarrhea ipi  005 administration yeast peptide neonatal lamb markedly elevated level antiinflammatory factor IL4 IL10 concurrently suppressing level proinflammatory factor IL1β IL6 colonic mucosa ipi  005 Furthermore yeast peptide enhanced intestinal antioxidant capacity ultimately strengthened colonic barrier function ipi  005 Supplementation yeast peptide altered colonic microbiota lambs characterized marked increase iRoseburiai decrease iStaphylococcusi iEscherichiaShigellai abundances Correlation analysis revealed observed attenuation inflammatory response enhancement barrier function associated enrichment iRoseburiai suppression iStaphylococcusi iEscherichiaShigellai conclusion yeast peptide demonstrate potential ameliorating diarrhea lamb modulation microbial community enhancement barrier function colon lambs recommended dosage yeast peptide 2000 mgd",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40792054/",
        "source_type": "Global"
    },
    {
        "pmid": "40792001",
        "title": "Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.",
        "abstract": "compare efficacy safety semaglutide liraglutide one year obese Polish patient type 2 diabetes prospective observational cohort study conducted Poland 2024 460 patient aged 1880 enrolled 333 received semaglutide Group 1 133 received liraglutide Group 2 12 months HbA1c level significantly decreased groups Group 1 609 ± 114 542 ± 082 mean decrease 067 ± 037 ipi00001 Group 2 578 ± 075 517 ± 054 mean decrease 061 ± 028 ipi0001 BMI decreased 536 ± 345 kgm² Group 1 441 ± 463 kgm² Group 2 ipi00001 greater reduction Group 1 ipi0017 Gastrointestinal adverse effect common including nausea vomiting constipation gastritis diarrhea higher incidence Group 1 HbA1c reduction correlated baseline HbA1c age gender BMI reduction correlated baseline HbA1c BMI Semaglutide effective liraglutide reducing HbA1c BMI Gastrointestinal symptom frequent side effect groups",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40792001/",
        "source_type": "Global"
    },
    {
        "pmid": "40789701",
        "title": "Robotic cholecystectomy with cholecysto-duodenal fistula division.",
        "abstract": "Cholecystoduodenal fistula CDF rare complication chronic calculous cholecystitis Due advancement minimally invasive techniques paradigm shift occurred traditional open surgery laparoscopic repair one case report highlight robotic repair article report case CDF management using robotic approach woman 50 history laparoscopic RouxenY gastric bypass surgery presented postprandial right upper quadrant abdominal pain associated diarrhoea Abdominal ultrasound showed cholelithiasis dilated common bile duct contain gallstone based magnetic resonance cholangiopancreatography MRCP underwent roboticassisted laparoscopic cholecystectomy found CDF divided robotically patient uneventful recovery case report discusses advantage robots enhanced visualisation dense adhesion three dimensions eliminating need conversion open surgery",
        "mesh_terms": [
            "Humans",
            "Female",
            "Robotic Surgical Procedures",
            "Intestinal Fistula",
            "Middle Aged",
            "Cholecystectomy, Laparoscopic",
            "Biliary Fistula",
            "Duodenal Diseases",
            "Cholangiopancreatography, Magnetic Resonance"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789701/",
        "source_type": "Global"
    },
    {
        "pmid": "40789179",
        "title": "Irritable Bowel Syndrome.",
        "abstract": "Irritable bowel syndrome IBS common gastrointestinal disorder prevalence 4 10 chronic condition characterized abdominal pain conjunction altered bowel habits abdominal distention bloating IBS present 3 different defecation patterns IBS constipation IBS diarrhea mixed IBS Recent advance IBS include positive diagnosis based symptombased criterion treatment plan based IBS subtype bothersome symptoms addition diet lifestyle modifications article discusses role new pharmacologic nonpharmacologic treatment option management IBS",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789179/",
        "source_type": "Global"
    },
    {
        "pmid": "40788605",
        "title": "Can symptoms and medical history predict outcomes for hydrogen and methane breath testing?",
        "abstract": "Hydrogen methane breath testing HMBT used diagnose small intestinal bacterial overgrowth SIBO intestinal methanogen overgrowth IMO limited data whether symptom medical history predict outcome lactulose HMBT large surveybased study conducted 731 subject completed lactulose HMBT single tertiary centre UK 32item survey included question relating symptom medical history Survey item statistically interrogated determine association SIBO IMO breath gas production using fishers exact test regression models SIBO determined rise ≥20 ppm breath hydrogen baseline within 90minutes IMO presence ≥10 ppm methane breath sample Abdominal pain p  0022 excessive belching p  0041 regurgitation p  0034 associated SIBO well daily abdominal pain diarrhoea P  0035 abdominal pain discomfort immediately eating OR 220 95 CI 129 379 Patients reporting least one skin condition likely test positive SIBO trend towards significance eczema p  0051 rosacea p  0067 IMO associated constipation p  0001 fattygreasy stool tend float p  0001 large questionnaire study demonstrated IBSlike symptoms refractory gastroesophageal reflux symptoms skin condition associated outcome HMBT finding support use HMBT accordance current clinical guidelines",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788605/",
        "source_type": "Global"
    },
    {
        "pmid": "40788441",
        "title": "Assessing participants' experiences with the COVID-19 symptom diary in a clinical trial.",
        "abstract": "phase 23 study twicedaily nirmatrelvir 300 mg coadministered ritonavir 100 mg versus placebo 5 day NCT05011513 participant reported presence severity COVID19 symptom using COVID19 symptom diary accordance FDA guidance Here aimed evaluate content validity COVID19 symptom diary global impression item qualitative interview recommended FDA Study participant kept daily electronic diary record presence severity 14 COVID19 symptom stuffy runny nose sore throat shortness breath cough low energy tiredness muscle body aches headache chillsshivering feeling hot feverish nausea frequency vomiting frequency diarrhea sense smell sense taste also answered question regarding 3 global impression item return health return usual activities overall symptom severity subset clinical trial participant interviewed study completion assess content validity diary Overall 25 participant interviewed across 10 clinical sites 14 symptom included diary reported ≥ 1 participant low energytiredness reported frequently 880 Twelve participant 480 reported ≥ 1 symptom captured diary dizziness common 120 Rates symptom lower ≤ 120 14 prespecified symptom included diary 160880 Based participant feedback 14 diary item clear generally easy answer using response scales interpreted intended 3 global item received similar feedback although participant noted challenge interpreting items describing question vague confusing response limited onethird reported difficulty calculating overall symptom experience multiple symptoms Participants reported electronic application diary global item easy use enabled item easily completed Exit interview result support content validity COVID19 symptom diary global impression items 14 symptom included diary reflecting commonly experienced COVID19 symptoms NCT05011513 httpsclassicclinicaltrialsgovct2showNCT05011513 ",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "COVID-19",
            "COVID-19 Drug Treatment",
            "Diaries as Topic",
            "Ritonavir",
            "SARS-CoV-2",
            "Severity of Illness Index",
            "Lactams",
            "Leucine",
            "Nitriles",
            "Proline"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788441/",
        "source_type": "Global"
    },
    {
        "pmid": "40788293",
        "title": "Disease and treatment awareness, prescription patterns, and self-medication practices in patients of functional bowel disorders: A cross-sectional survey.",
        "abstract": "Functional bowel disorder FBD chronic recurrent debilitating disorder affecting mid lower gastrointestinal tract identifiable underlying pathology dearth Indian study focusing treatment awareness prescription evaluation FBD Due chronic course patient tend selfmedicate study planned evaluate disease drug treatment awareness selfmedication practices prescription pattern FBD patients crosssectional singlecenter questionnairebased study carried FBD patient getting clearance Institutional Ethics Committee patient administered two questionnaires ie diseasedrug awareness selfmedication questionnaire Prescriptions analyzed based World Health Organization prescribing indicators total 118 FBD patient enrolled common disorder functional constipation 94118 797 Number male 77118 65 greater female 41118 34 disease awareness 98118 83 patient opined FBD occurs frequently agreed medication treat FBD treatment awareness 106118 90 patient aware importance drug compliance 10118 9 knew adverse effects prescription patterns total 311 medication prescribed total 173 medication primary drug FBD Laxatives common class 98138 689 prescribed polyethylene glycol 77138 557 common drug prescribed functional constipation total 28118 237 patients selfmedicated prior visiting current OPD FBD patient aware dosing schedule consulted treating doctor awareness regarding drug name adverse effect poor among patients Laxativepolyethylene glycol common drug prescribed less 14 th patient resorted selfmedication commonly herbal remedies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788293/",
        "source_type": "Global"
    },
    {
        "pmid": "40788172",
        "title": "Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial results.",
        "abstract": "MDM2 E3 ubiquitin ligase degrades tumor suppressor p53 cancers MDM2 amplification MDM2amp lead overexpression MDM2 inducing p53 degradation p53null phenotype even absence TP53 mutations report preclinical clinical activity milademetan potent selective oral small molecule inhibitor MDM2p53 interaction MDM2amp TP53wildtype wt solid tumors Milademetan tested variety cellline xenograft tumor models supported phase II basket study MANTRA2 patient advanced MDM2amp TP53wt solid tumors primary endpoint objective response rate ORR key secondary endpoint included progressionfree survival PFS adverse events Milademetan showed potent activity MDM2amp TP53wt laboratory models phase II trial 40 patient received milademetan 31 centrally confirmed molecular testing best overall response 194 631 1 confirmed response 32 5 unconfirmed partial responses including patient endometrial stromal sarcoma achieved 100 target lesion reduction median PFS 35 month 95 CI18 37 Grade 3 4 adverse event observed included thrombocytopenia neutropenia anemia leukopenia diarrhea Milademetan manageable safety profile achieved response variety refractory MDM2amp TP53 wt solid tumors tumor reduction shortlived Subsequent MDM2 inhibitor effort focus combination strategy treatment earlier line therapy achieve durable clinical benefit",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788172/",
        "source_type": "Global"
    },
    {
        "pmid": "40787502",
        "title": "Efficacy of botulinum toxin in the treatment of chronic anal fissure: a comprehensive systematic review.",
        "abstract": "Acute anal fissure maintains debilitating state produce enduring wound damage anal mucosa internal anal sphincter demonstrates increased muscle tone study aim conduct comprehensive systematic review evaluate efficacy botulinum toxin BT treatment chronic anal fissure synthesizing current evidence clinical trial observational study guide evidencebased practice review systematic research investigates performance security along extended outcome linked BT therapy treating chronic anal fissure analyzing 23 clinical studies healing response BT injection reach 6085 without producing headache side effect commonly experienced topical glyceryl trinitrate GTN medications Lateral internal sphincterotomy LIS produce excellent longterm healing result 9095 cases although lead fecal incontinence risk 515 rate Expanding BT treatment usually necessitates additional injection surgical intervention high rate recurrence 13 year 3040 Combining Botox treatment GTN administration achieves healing rate 70 80 study provide inconsistent research data optimal dosage range BT treatment 2030 units Botox performs equally well Dysport achieving results BT provides patient want surgery benefit safe minimally invasive procedure time LIS offer definitive solution patient cannot respond treatments Research must establish standardized dose instruction improving injection method developing extended strategy stop relapses",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40787502/",
        "source_type": "Global"
    },
    {
        "pmid": "40787254",
        "title": "Effect of Sodium Butyrate and Sishen Pill Combination on Diarrhea with Kidney-Yang Deficiency Syndrome Was Associated with Intestinal Mucosal Microbiota and Immune Barrier.",
        "abstract": "investigate therapeutic mechanism sodium butyrate combined SSP treating diarrhea kidneyyang deficiency syndrome providing experimental evidence modern application classical Chinese medicine formulas mouse model diarrhea kidneyyang deficiency syndrome established via adenine combined iFolium sennaei gavage successful model establishment drug intervention group administered gavage 100 SSP decoction 300 mgmL sodium butyrate 100 mgkg sodium butyrate  50 SSP decoction respectively General physical condition organ index assessed Serum tumor necrosis factorα TNFα interleukin6 IL6 levels well colonic immunoglobulin sIgA mucin 2 MUC2 levels determined via ELISA Kidney intestinal histology evaluated via hematoxylin‒eosin HE staining characteristic small intestinal mucosal microbiota different intervention analysed via 16S rRNA sequencing Compared natural recovery combination 100 mgkg sodium butyrate  50 SSP significantly restored colonic sIgA level ipi 005 MUC2 levels indicating improvement intestinal mucosal barrier function Histological analysis revealed combination 100 mgkg sodium butyrate  50 SSP improved renal inflammation restored intestinal villus length crypt depth combination therapy controlled relative abundance iCorynebacteriumi restoring iDwaynesavagellai iMegasphaeraAi Correlation analysis indicated iMammaliicoccusi iCorynebacteriumi significantly negatively correlated sIgA MUC2 level relative abundance inhibited combination therapy Sodium butyrate enhanced therapeutic efficacy SSP combination therapy effectively repaired damaged kidney intestine alleviated diarrhea kidneyYang deficiency syndrome modulating relative abundance intestinal microbiota enhancing intestinal immunity well mucosal barrier function interaction intestinal microbiota intestinal mucosal protective factor may key mechanism combined treatment diarrhea kidneyyang deficiency syndrome",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40787254/",
        "source_type": "Global"
    },
    {
        "pmid": "40787184",
        "title": "Definitive Chemoradiation Followed by Consolidation Immunotherapy for Unresectable Tracheal Squamous Cell Carcinoma: A Case Report.",
        "abstract": "Tracheal cancer rare malignancy typically treated multimodal approach surgery radiation therapy chemotherapy Despite treatment options outcome poor high risk recurrence lifethreatening present case 68yearold male unresectable squamous cell carcinoma SCC trachea treated definitive concurrent chemoradiation 66 Gy cisplatin followed consolidation immunotherapy durvalumab treatment approach mirror regimen used unresectable stage III nonsmall cell lung cancer NSCLC based PACIFIC trial patient began durvalumab six week chemoradiation received five cycle 25 months therapy discontinued early due immunemediated colitis presenting diarrhea immunotherapyrelated autoimmune side effect successfully managed since undergone routine surveillance serial positron emission tomographycomputed tomography PETCT imaging clinical followup remains diseasefree three year posttreatment case demonstrates potential benefit adapting NSCLC immunotherapy regimen primary tracheal squamous cell carcinoma SCC standardized postchemoradiation immunotherapy protocol",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40787184/",
        "source_type": "Global"
    },
    {
        "pmid": "40786849",
        "title": "Infection of <i>Enterocytozoon bieneusi</i> in a Patient with Long-Term Immunosuppression after Liver Transplantation: A Case Report and Literature Review.",
        "abstract": "iEnterocytozoon bieneusii iEbi cause opportunistic infection immunocompromised patients especially HIVAIDS recipients currently still case report iEbi infection solid organ transplant recipients iEbi cannot diagnosed routine examination culture often overlooked possible cause chronic diarrhea transplant recipients known established guideline iEbi effective available treatment option limited article reported case persistent chronic diarrhea renal failure due iEbi infection liver transplantation definitively diagnosed using metagenomic nextgeneration sequencing mNGS Short course albendazole applied patient resulting rapid resolution clinical symptom recovery renal function case demonstrates advantage mNGS diagnosis rare pathogenic bacterial infections together previous case reports suggests albendazole may serve effective therapy treatment iEbi patient article review relevant literature provides updated comprehensive reference selection iEbi treatment drugs note overview showed may individualized difference efficacy albendazole need study",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786849/",
        "source_type": "Global"
    },
    {
        "pmid": "40786340",
        "title": "An Unusual Case of Pylephlebitis With the Involvement of Portal and Superior Mesenteric Veins.",
        "abstract": "Pylephlebitis lowincidence condition worldwide commonly affecting adult population clinical presentation nonspecific thus requiring detailed clinical history confirmation imaging study contrastenhanced computed tomography literature recommends antibiotic treatment least six week use anticoagulants diagnosed treated early prognosis generally favorable report present case pylephlebitis clinical symptom fever vomiting diarrhea patient diagnosed pylephlebitis involving right left portal vein superior mesenteric vein showed clinical improvement following treatment broadspectrum antibiotic anticoagulants",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786340/",
        "source_type": "Global"
    },
    {
        "pmid": "40786287",
        "title": "Contained Perforation of a Jejunal Diverticulum in an Elderly Patient: A Case Report.",
        "abstract": "Jejunal diverticulosis uncommon condition complicationssuch perforationpose diagnostic therapeutic challenge particularly elderly patients Contained perforation especially difficult identify due nonspecific clinical presentation subtle radiological findings report case 82yearold woman medical history atrial fibrillation heart failure chronic obstructive pulmonary disease COPD irritable bowel syndrome presented emergency department twoday history diffuse abdominal pain nausea vomiting diarrhea Physical examination revealed abdominal distension tenderness epigastric mesogastric regions without sign peritoneal irritation Laboratory test showed leukocytosis impaired renal hepatic function Although initial imaging study suggested possible bowel obstruction noncontrastenhanced abdominopelvic computed tomography CT scan diagnostic demonstrated multiple jejunal diverticula one exhibited elongated morphology wall thinning adjacent mesenteric fat strandingfindings consistent contained perforation Due persistent symptom despite conservative management exploratory laparotomy performed Intraoperatively perforated jejunal diverticulum identified 90 cm distal ligament Treitz 5 cm segmental small bowel resection performed followed stapled sidetoside anastomosis functionally endtoend configuration postoperative course uneventful patient discharged postoperative day four favorable outpatient followup case underscore importance considering complicated jejunal diverticulitis differential diagnosis acute abdominal pain elderly patients even presence atypical clinical findings noncontrast CT scan essential early identification contained perforation allowing timely surgical intervention favorable outcome high index clinical suspicion crucial patient population avoid potentially fatal diagnostic delays",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786287/",
        "source_type": "Global"
    },
    {
        "pmid": "40786213",
        "title": "Short febrile illness with rashes and diarrhea after clozapine therapy: A case report.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786213/",
        "source_type": "Global"
    },
    {
        "pmid": "40785902",
        "title": "Donafenib <i>vs.</i> lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study.",
        "abstract": "combination tyrosine kinase inhibitor TKIs transarterial chemoembolization TACE hold promise unresectable hepatocellular carcinoma HCC study aimed directly compare efficacy safety donafenib DonaTACE ivsi lenvatinib LENTACE firstline therapies retrospective study 93 unresectable HCC patient 49 DonaTACE 44 LENTACE 93 hepatitis B virusinfected treated October 2020 May 2023 analyzed Patients received TACE conventional drugeluting beads combined Dona 200 mg twice daily LEN 812 mgday Outcomes included overall survival OS progressionfree survival PFS objective response rate ORR disease control rate DCR adverse event AEs Survival analysis employed KaplanMeier logrank tests Median OS mOS 1400 month DonaTACE ivsi 1900 month LENTACE hazard ratio HR 125 95 confidence interval CI 078199 P0330 Median PFS 737 ivsi 577 month HR 0785 95 CI 046133 P0354 significant differences ORR 5510 ivsi 6136 P0541 DCR 7551 ivsi 8182 P0460 comparable DonaTACE showed significantly lower overall AE rate any grade 8571 ivsi 10000 P0013 grade ≥3 2245 ivsi 4545 P0027 including reduced hypertension 204 ivsi 3636 P0001 diarrhea 612 ivsi 2500 P0011 vomiting 000 ivsi 4091 P0001 DonaTACE LENTACE demonstrated comparable efficacy unresectable HCC DonaTACE exhibited superior safety profile suggesting potential preferable option patient higher comorbidity risks prospective study warranted validate findings",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785902/",
        "source_type": "Global"
    },
    {
        "pmid": "40785798",
        "title": "Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist.",
        "abstract": "advent combination immunotherapy revolutionized treatment metastatic renal cell carcinoma mRCC leveraging immune checkpoint inhibitor tyrosine kinase inhibitor improve survival outcomes However advancement come significant challenge management adverse effects impair patients quality life lead therapy discontinuation review explores prevalence mechanisms management gastrointestinal GI toxicity associated immunotherapy combination mRCC gastroenterologists perspective Diarrhea colitis nausea vomiting frequently reported adverse events often necessitating multidisciplinary approach timely diagnosis intervention mitigate risk ensure therapeutic continuity highlight management strategies ranging symptomatic treatment dietary modification advanced therapy severe cases even discussing emerging approach refractory cases integrating oncological gastroenterological expertise clinician optimize outcome patient minimizing GIrelated complications",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785798/",
        "source_type": "Global"
    },
    {
        "pmid": "40785621",
        "title": "Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.",
        "abstract": "Studies indicated afatinib combined angiogenesis inhibitor may achieve promising efficacy nonsmall cell lung cancer NSCLC patient epidermal growth factor receptor EGFR mutations multicenter Phase II trial explore efficacy safety afatinib plus bevacizumab firstline setting EGFRmutant NSCLC patients primary end point progressionfree survival PFS secondary end point included objective response rate ORR disease control rate DCR safety July 11 2020 November 11 2021 54 treatmentnaïve NSCLC patient enrolled afatinib plus bevacizumab combination cohort Meanwhile 81 NSCLC patient EGFR mutation treated firstline afatinib monotherapy retrospectively collected median followup time 266 months significant difference PFS observed afatinib plus bevacizumab combination cohort afatinib monotherapy cohort 145 vs 122 months HR 087 p  015 confirmed propensity score matching PSM analysis Patients pleural metastasis HR 056 95 CI 032098 p  005 uncommon EGFR mutation HR 061 95 CI 025147 p  005 experienced longer PFS combination cohort ORR combination cohort favorable afatinib monotherapy cohort 778 vs 420 p  005 Diarrhea common treatmentrelated adverse event TRAEs 111 654 patient grade ≥ 3 TRAEs treated afatinib plus bevacizumab Afatinib combined bevacizumab well tolerated moderate efficacy among patient NSCLC might prospective strategy patient uncommon EGFR mutation pleural metastasis wwwchictrorgcn",
        "mesh_terms": [
            "Humans",
            "Bevacizumab",
            "Male",
            "Afatinib",
            "Carcinoma, Non-Small-Cell Lung",
            "Female",
            "Lung Neoplasms",
            "Middle Aged",
            "Aged",
            "Mutation",
            "ErbB Receptors",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Adult",
            "Retrospective Studies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785621/",
        "source_type": "Global"
    },
    {
        "pmid": "40785148",
        "title": "Colonic Stricture Formation in a Dog Treated for Acute Hemorrhagic Diarrhea Syndrome With a Rectal Foley Catheter.",
        "abstract": "describe complication subsequent surgical management colonic stricture associated use rectal Foley catheter treatment dog acute hemorrhagic diarrhea syndrome 5yearold intact female Poodle mix initially presented 1224h history bloody diarrhea lethargy diagnosis severe acute hemorrhagic diarrhea syndrome made dog hospitalized supportive care including placement 18French rectal Foley catheter reduce patient fecal contamination Fourquadrant antibiotic therapy started sign sepsis identified rectal Foley catheter remained place 72 h removal patient made full recovery discharged 5 day initial presentation Four week later patient returned 10day history obstipation hyporexia intermittent vomiting colonoscopy performed identified complete colonic stricture consistent previous site rectal Foley catheter retention balloon stricture could dilated rectal balloon catheter subsequently dog underwent colonic resection anastomosis Within hour postoperatively dog passed feces discharged following day 12month followup patient clinically well recurrence obstipation tenesmus Risks associated rectal Foley catheter use dog previously reported therefore treating clinician carefully consider potential complication placement authors knowledge first paper veterinary medicine document complication associated use rectal Foley catheter dog",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785148/",
        "source_type": "Global"
    },
    {
        "pmid": "40784986",
        "title": "Afatinib amplifies cAMP-induced fluid secretion in a mouse mini-gut model via TMEM16A-mediated fluid secretion and secretory cell differentiation.",
        "abstract": "Afatinib effective treatment metastatic nonsmall cell lung cancer despite occurrence common gastrointestinal toxicity especially diarrheas lead dose adjustment treatment cessation severe cases Underlying mechanism afatinibinduced diarrhea prolonged treatment remain elusive study aimed investigate mechanism involved afatinibinduced fluid secretion threedimensional 3D mouse minigut model prolonged treatment 24 h swelling assay qRTPCR immunoblotting experiment performed result showed afatinib amplified cAMPinduced fluid secretion 2 fold mechanism requiring TMEM16A Ksubvsub7 channel via EPACcalciumdependent pathways Additionally afatinib treatment increased Ksubvsub71 NKCC1 expression Interestingly afatinib induced secretory cell differentiation upregulation Paneth cell markers Treatment PI3K inhibitor mimicked effect afatinib increasing expression membrane transporter secretory lineage cell marker additive effect observed combination afatinib suggesting observed effect afatinib via PI3K inhibition Collectively result indicate prolonged afatinib treatment enhances cAMPinduced fluid secretion mechanism involving EPACTMEM16AKsubvsub71mediated fluid secretion secretory cell differentiation 3D mouse minigut models EPACTMEM16AKsubvsub71mediated fluid secretion represents promising therapeutic target treating afatinibinduced diarrheas",
        "mesh_terms": [
            "Animals",
            "Anoctamin-1",
            "Mice",
            "Cell Differentiation",
            "Afatinib",
            "Cyclic AMP",
            "Guanine Nucleotide Exchange Factors",
            "Diarrhea"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784986/",
        "source_type": "Global"
    },
    {
        "pmid": "40784972",
        "title": "Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome.",
        "abstract": "safety efficacy microbiotabased product patient irritable bowel syndrome IBS recurrent Clostridioides difficile infection rCDI studied Fecal microbiota livejslm RBL REBYOTAsup®sup FDAapproved singledose microbiotabased product prevent rCDI adult following standardofcare SOC antibiotic treatment exploratory subgroup analysis PUNCH CD3OLS phase 3 openlabel prospective study conducted United States US Canada evaluate safety efficacy RBL participant documented rCDI concurrent IBS Participants aged ≥ 18 year diagnosis rCDI completed SOC antibiotic treatment enrolled study primary endpoint PUNCH CD3OLS number participant RBL administrationrelated treatmentemergent adverse event TEAEs Secondary endpoint included treatment success 8 week sustained clinical response 6 months subgroup analysis ongoing IBS confirmed based medical record documentation time RBL administration Among 697 RBL recipients 90 comorbid IBS RBL administration 52 participant IBS 578 278 participant without IBS 458 experienced TEAEs 8 weeks TEAEs mild 222 IBS 201 without IBS moderate 267 IBS 188 without IBS Serious TEAEs reported 1 participant IBS pneumonia reported unrelated RBL 26 participant without IBS most related preexisting condition 31 Among participants 689 IBS 756 without IBS absence CDI diarrhea 8 week RBL administration participant treatment success 823 IBS 922 without IBS sustained clinical response 6 months RBL safe efficacious option prevent CDI recurrence patient concurrent IBS ClinicalTrialsgov identifier NCT03931941",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784972/",
        "source_type": "Global"
    },
    {
        "pmid": "40784408",
        "title": "Incidence of and risk factors for side effects associated with antibiotic treatment for pneumonia.",
        "abstract": "determine incidence side effect associated betalactam antibiotic commonly used pneumonia treatment risk factor side effect Patients communityacquired healthcareassociated pneumonia prospectively enrolled June 2002 December 2012 Patients administered betalactam antibiotic treatment pneumonia side effect observed antibiotic treatment recorded Multivariate analysis performed identify independent risk factor side effect total 1162 patient enrolled study antibiotic used treatment ampicillinsulbactam 362 piperacillintazobactam 111 cefotiam 89 ceftriaxone 140 cefepime 130 imipenemcilastatin 110 meropenem 97 others 123 cases Diarrhea elevated liver enzyme levels skin rash observed 174 150  52 45  28 24  patients respectively multivariate analysis female sex p  005 use either piperacillintazobactam p  005 cefepime p  005 imipenemcilastatin p  005 significantly associated diarrhea Use cefotiam p  005 meropenem p  005 significantly associated elevated liver enzyme levels significant risk factor found skin rashes Broadspectrum antibiotic tended cause diarrhea frequently use cefotiam meropenem associated increased liver enzyme levels",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784408/",
        "source_type": "Global"
    },
    {
        "pmid": "40783009",
        "title": "The role of microbial-derived p-Cresol in autism spectrum disorder: A systematic review of the gut-brain axis.",
        "abstract": "Autism Spectrum Disorder ASD complex neurodevelopmental condition increasingly associated gut microbiota alterations Among microbial metabolites pCresol emerged potential contributor pathophysiology ASD systematic review aim examine evidence linking pCresol metabolite ASD explore potential role within gutbrain axis framework bidirectional communication system gut microbiota influence brain function via immune metabolic neural pathway eg vagus nerve microbial metabolites comprehensive literature search conducted PubMed Web Science Scopus Cochrane March 2025 following PRISMA 2020 guidelines Studies included quantified pCresol derivative biological sample individual ASD Data extraction risk bias assessment performed independently two reviewers protocol prospectively registered PROSPERO CRD420251007080 Seventeen study met inclusion criteria reported elevated urinary fecal pCresol level individual ASD compared controls consistent association found pCresol concentration 1 gastrointestinal symptoms particularly constipation diarrhea 2 specific microbiota alteration including increased Clostridium difficile Desulfovibrio abundance 3 behavioral manifestation ASD severity However heterogeneity study designs small sample sizes variability analytical technique limit generalizability results pCresol microbial precursor may contribute ASD pathophysiology gutbrain axis interactions Although current evidence support association longitudinal mechanistic study needed confirm causality evaluate pCresol biomarker therapeutic target ASD",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40783009/",
        "source_type": "Global"
    },
    {
        "pmid": "40782291",
        "title": "Safety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy: A 12‑Month Interim Analysis of a Postmarketing Surveillance Study.",
        "abstract": "Risdiplam oral splicing modifier survival motor neuron2 gene SMN2 approved treating spinal muscular atrophy SMA safety efficacy demonstrated global trials limited realworld data safety Japanese patient SMA allcase postmarketing surveillance PMS study aimed assess safety usage pattern risdiplam Japan 12month interim analysis part ongoing PMS study includes Japanese patient SMA received risdiplam full observation period PMS 24 month initiation risdiplam treatment Safety data including adverse drug reaction ADRs collected case report form CRFs submitted participating healthcare facilities ADRs coded using MedDRAJ classification study included 538 patient SMA 259 institution Japan August 2021 August 2022 median age minimummaximum enrolment 225 083 years 515 patient male SMA type II 472 III 279 common phenotypes median treatment duration 3660 days 861 patient continued risdiplam treatment ADRs reported 112 patient 208 serious ADRs reported eight patient 15 common ADRs classified MedDRA System Organ Class gastrointestinal disorder 86 160 patient diarrhoea 43 80 faeces soft 23 43 stomatitis 10 19 patients Exploratory analysis suggested advanced age comorbidities concomitant medication use might associated increased incidence gastrointestinal ADRs 12month interim analysis PMS data indicated risdiplam well tolerated among Japanese patient SMA consistent previous clinical trial findings comprehensive evaluation safety efficacy risdiplam provided final 24month analysis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40782291/",
        "source_type": "Global"
    },
    {
        "pmid": "40782264",
        "title": "Severe immune-related adverse event colitis successfully treated with single-dose infliximab in an older adult with hepatocellular carcinoma receiving STRIDE therapy.",
        "abstract": "Severe immunerelated adverse event irAEs steroidrefractory patient remain clinical challenge among older patient hepatocellular carcinoma HCC treated immune checkpoint inhibitors Although infliximab recommended steroidrefractory irAE colitis safety outcome older patient liver disease remain unclear Here report case highlight safety effectiveness singledose infliximab steroidrefractory irAE colitis older patient HCC 84yearold man alcoholrelated HCC received STRIDE therapy durvalumab plus tremelimumab day 35 developed severe headache followed watery bloody diarrhea day 40 Based clinical course endoscopic findings patient diagnosed grade 4 irAE colitis condition refractory prednisolone 60 mgday single dose infliximab 400 mg administered day 5 steroid therapy Rapid clinical improvement remission observed lenvatinib resumed day 220 without irAE recurrence Singledose infliximab may safe effective option severe irAE colitis older patient HCC allowing continuation cancer therapy case may serve practical reference clinician managing severe irAEs highrisk populations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40782264/",
        "source_type": "Global"
    },
    {
        "pmid": "40782189",
        "title": "Canine Microencapsulated Probiotic Formulations Modulate Immunity and Improve Acute Diarrhea in Dogs.",
        "abstract": "Hostderived probiotic strain offer effective alternative antibiotic improving animal gastrointestinal health study two probiotic strainsLactiplantibacillus plantarum TUCO16 Lacticaseibacillus rhamnosus TUCO17isolated initially canine colostrum milk scaled formulated oligosaccharide freezedried preparations formulation evaluated vitro using canine human cell model assess cytotoxicity adhesion capacity immunerelated gene expression reactive oxygen specie ROS production paracellular permeability strain demonstrated high adhesion 92 p  0001 cytotoxic effects induced significant p  00001 expression pro antiinflammatory cytokines also stimulated expression mucin tight junction protein epithelial cell increase 414fold 21fold p  00001 respectively addition formulation enhanced ROS production macrophage p  00001 maintained reduced epithelial permeability p  00001 vivo trial dog acute diarrhea confirmed safety formulations showed improvement stool consistency end treatment without affecting frequency contrasting effect metronidazole Overall result support using hostspecific probiotic immunomodulatory agent enhance intestinal barrier integrity offer safe antibioticfree alternative managing acute diarrhea dogs",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40782189/",
        "source_type": "Global"
    },
    {
        "pmid": "40781941",
        "title": "Comparison of depressive symptoms between patients with myeloproliferative neoplasms without the Philadelphia chromosome treated with interferon alpha and patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.",
        "abstract": "aim study compare occurrence depressive symptom group patient MPN essential thrombocythemia polycythemia vera primary myelofibrosis treated interferonalpha patient chronic myelogenous leukaemia CML treated tyrosine kinase inhibitor check whether individual side effect may contribute occurrence depressive symptoms study involved 175 adult patient MPN CML treated IFNα TKI minimum 3 months study used David Goldberg Questionnaire GHQ28 FourDimensional Questionnaire 4DSQ survey Approximately 40 patient MPN almost 20 patient CML obtained moderately strongly elevated score depression scale analysis revealed statistically significant difference woman men Bone joint pain β0196 p0013 nausea indigestion β0191 p0007 fatigue β0136 p0053 cramp muscle ache β0159 p0038 diarrhoea β0138 p0050 side effect affected possibility developing depressive symptom groups common predictor depressive symptom number side effects type illness age older person was greater severity depressive symptoms significant difference prevalence depression patient CML MPN Specific side effect interferonalpha TKI treatment influence occurrence depressive symptoms association interferon treatment development depression confirmed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781941/",
        "source_type": "Global"
    },
    {
        "pmid": "40781661",
        "title": "Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database.",
        "abstract": "study sought comprehensively evaluate safety profile tremelimumab durvalumab patient hepatocellular carcinoma HCC examining adverse drug reaction ADR documented Food Drug Administrations Adverse Event Reporting System FAERS database Data FAERS database spanning first quarter 2004 first quarter 2025 extracted filtered standardized Reporting Odds Ratio ROR Bayesian Confidence Propagation Neural Network BCPNN method utilized analyze signal strength identify potential ADRs total 574 case 1021 ADR report identified Gastrointestinal disorder 1565 n  188 hepatobiliary disorder 1216 n  146 general disorder administration site condition 1174 n  141 emerged frequently reported category system organ class SOC Death diarrhea malignant neoplasm progression identified three common preferred term PT based reporting frequency Immunemediated ADRs elevated ROR BCPNN value prevalent across multiple systems particularly within gastrointestinal 52822 903 hepatic 86382 970 cardiac 36524 849 endocrine 32126 831 dermatological 74471 951 domains study underscored intricate safety profile tremelimumab durvalumab HCC patients characterized predominantly immunemediated toxicity significant gastrointestinal hepatobiliary risks Utilization drug necessitated meticulous patient selection multidisciplinary management approach optimize patient outcome mitigate ADRs",
        "mesh_terms": [
            "Humans",
            "Carcinoma, Hepatocellular",
            "Liver Neoplasms",
            "Adverse Drug Reaction Reporting Systems",
            "United States Food and Drug Administration",
            "Antibodies, Monoclonal, Humanized",
            "United States",
            "Antibodies, Monoclonal",
            "Male",
            "Female",
            "Middle Aged",
            "Databases, Factual",
            "Aged",
            "Adult",
            "Aged, 80 and over",
            "Antineoplastic Agents, Immunological",
            "Drug-Related Side Effects and Adverse Reactions",
            "Bayes Theorem"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781661/",
        "source_type": "Global"
    },
    {
        "pmid": "40780642",
        "title": "High lignan- and flavonoid-based polyherbal mixtures improve performance in Holstein calves via modulating diarrhea frequency, rumen volatile fatty acid levels, and serum health parameters.",
        "abstract": "study aimed determine effect polyherbal mixture PM containing 423 lignans 212 flavonoid performance ruminal fermentation serum biomarkers preweaning Holstein calves Sixtyfour neonatal calf 406 ± 43 kg BW 48 female 16 males allocated randomized complete block design stratified birth weight birth date sex Starter feed provided ad libitum 4 weaning Treatments included control no PM supplementation milk milk combined PM supplement 10 20 40 gd result revealed feed efficiency body length heart girth significantly differ among treatments However BW DMI ADG wither height shank circumference increased linearly increasing PM supplementation diarrhea frequency decreased linearly 4 15 Ruminal ammonianitrogen molar proportion individual VFA significantly affected PM supplementation ruminal pH total VFA showed linear decrease increase increasing PM respectively Similarly serum glucose BUN total protein albumin globulin aspartate aminotransferase alanine aminotransferase IL6 IgM significantly affected PM supplementation triglyceride concentration showed quadratic cubic decrease increasing PM IGF1 concentration total antioxidant capacity IL10 concentration increased linearly tumor necrosis factorα concentration increased quadratically increasing PM supplementation conclusion PM addition improved growth performance preweaning Holstein calf reduced diarrhea frequency PM supplementation 40 gd exerting significant effect",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40780642/",
        "source_type": "Global"
    },
    {
        "pmid": "40778736",
        "title": "Effects of manual acupuncture on fatty acid metabolism in a rat model of diarrhea-predominant irritable bowel syndrome: a multi-tissue metabolomic and plasma lipidomic investigation.",
        "abstract": "Diarrheapredominant irritable bowel syndrome IBSD subtype IBS Many patient dissatisfied efficacy drug treatment seek complementary alternative medical therapies especially acupuncture treatment study evaluated effect manual acupuncture MA IBSD using rat model investigated underlying mechanism action analyzing change untargeted metabolomics plasmalivercolon targeted plasma lipidomics Thirty male SpragueDawley rat divided Control IBSD group n  10 each IBSDMA group received acetic acid enema combined restraint stress Control group received saline enemas group received daily ST36 2 week modeling Pain stool quality measured abdominal withdrawal reflex AWR Bristol stool form scale BSFS Plasmalivercolon sample collected ultrahigh performance liquid chromatography UHPLCQOrbitrap mass spectromy MS untargeted metabolomics Plasma also subjected UHPLCMSMS targeted lipidomics treatment improved BSFS AWR score IBSD model rats suggesting reduced intestinal hypersensitivity Metabolomic result showed impacted 18 metabolite plasma liver colon mainly involved arachidonic acid metabolism biosynthesis unsaturated fatty acids amino sugar nucleotide sugar metabolism Targeted lipidomic result showed restored low level four mediumchain one longchain fatty acid normal level IBSD suggesting acupuncture treatment IBSD involves fatty acid metabolic pathways reduced marker intestinal hypersensitivity impacted number metabolic pathway rat model IBSD",
        "mesh_terms": [
            "Animals",
            "Irritable Bowel Syndrome",
            "Rats, Sprague-Dawley",
            "Male",
            "Rats",
            "Fatty Acids",
            "Diarrhea",
            "Disease Models, Animal",
            "Lipidomics",
            "Acupuncture Therapy",
            "Metabolomics",
            "Humans",
            "Liver",
            "Colon"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40778736/",
        "source_type": "Global"
    },
    {
        "pmid": "40778205",
        "title": "Potential relationship between gut microbiota and animal diarrhea: a systematic review.",
        "abstract": "Diarrhea pose significant challenge growth livestock industry decreasing productivity increasing mortality rate animals Several factor bacteria viruses parasites stress identified potential contributor diarrhea gut microbiota complex microecosystem consisting trillion microorganism bacteria fungi viruses play key role host metabolism immunity nutrient absorption gut microbial homeostasis essential intestine perform physiological function maintain host health Conversely gut microbial dysbiosis lead development various diseases Recent research highlighted gut microbial dysbiosis driving factor animal diarrhea Consequently maintaining gut microbial homeostasis become key focus prevention treatment diarrhea review examines composition metabolite function gut microbiota well cause diarrhea alteration gut microbiota diarrhea Furthermore review provides insight future research field especially alleviating animal diarrhea gut microbial perspective",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40778205/",
        "source_type": "Global"
    },
    {
        "pmid": "40778139",
        "title": "Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.",
        "abstract": "Cancers respond immunotherapy typically harbor nonT cellinflamed tumor microenvironment TME characterized absence type III interferon IFN signaling CD8 supsup cell infiltration previously reported iIDH1i somatic mutation enriched nonT cellinflamed tumor across tumor types Consistent this mutant IDH1 mIDH1 demonstrated drive immune exclusion metabolic reprogramming TME IDH inhibition enhanced antitumor immunity preclinical models Based pancancer observations conducted Phase II study assessing preliminary activity ivosidenib IDH1 inhibitor combination nivolumab antiPD1 antibody patient mIDH1 advanced solid tumor  NCT04056910  Patients advanced refractory solid tumor harboring iIDH1i mutation prior exposure IDH1 inhibitor enrolled Participants administered ivosidenib 500 mg mouth daily nivolumab 480 mg intravenously every 4 weeks Given heterogeneity tumor types including RECIST response uncommon ie sarcoma composite primary endpoint utilized including either sixmonth progression free survival PFS6 overall response rate ORR Translational analysis included pharmacodynamic proteomic spatial transcriptomic investigations 15 patient enrolled median age 54 years female 533 ECOG 1 60 glioma 467 R132H 40 One patient partial response ORR 67 without progression 6 month PFS6 whereas two patient achieved PFS6 alone total 3 15 patient met primary endpoint 315 20 median PFS 194 months common treatment adverse event leukopenia 67 rash 67 diarrhea 33 nausea 27 QTC prolongation 27 Pharmacodynamic study demonstrated combining ivosidenib nivolumab significantly decreased plasma R2HG concentration correlated clinical benefit Serum proteomic spatial omic analysis suggested immunemodulatory effect mIDH1 inhibition plus antiPD1 treatment refractory mIDH1 solid tumors combination ivosidenib nivolumab safe however demonstrated similar antitumor activity predominantly disease stabilization compared previously described ivosidenib monotherapy Translational investigation suggests evaluation IDH1 inhibition combination partner immunecheckpoint inhibition may justified study demonstrates ivosidenib combined nivolumab safe patient advanced IDH1mutant solid tumors clinical activity modest comparable ivosidenib monotherapy Pharmacodynamic exploratory translational analysis revealed immunerelated change tumor microenvironment suggesting mutant IDH1 inhibition may modulate immune signaling finding support investigation IDH1 inhibitor immunotherapy partner highlight importance integrated translational analysis inform therapeutic development",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40778139/",
        "source_type": "Global"
    },
    {
        "pmid": "40777955",
        "title": "Factors associated with acute kidney injury and outcomes in patients with malaria in a district hospital in Rwanda.",
        "abstract": "Acute kidney injury AKI remains one complication severe malaria Evidence associated factor outcome patient complicated malaria AKI limited Rwanda assess factor associated acute kidney injury outcome patient malaria district hospital Rwanda retrospective study design applied census sampling strategy used select 122 file patient admitted severe malaria patient 20162017 developed clinical audit form used collect data patients files descriptive inferential statistic used analyze data Among confirmed severe malaria files 44 participant 50 year 525 males majority 915 communitybased health insurance 163 acute kidney injury significant associated clinical factor dehydration p01 highgrade fever p002 profuse sweating p034 vomiting p043 diarrhea p025 20 patient developed AKI 55 completely recovered 15 died 30 case transferred highest facility hemodialysis existence AKI among severe malaria patient evident recovering others dying need educating healthcare professionals mostly district hospital diagnosis management AKI result complicated malaria",
        "mesh_terms": [
            "Humans",
            "Acute Kidney Injury",
            "Male",
            "Female",
            "Rwanda",
            "Retrospective Studies",
            "Malaria",
            "Middle Aged",
            "Hospitals, District",
            "Adult",
            "Risk Factors",
            "Young Adult",
            "Adolescent",
            "Aged",
            "Dehydration",
            "Fever"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40777955/",
        "source_type": "Global"
    },
    {
        "pmid": "40777715",
        "title": "Clinical and Histological Co-occurrence of Tropical Sprue and Helicobacter pylori Infection in Northeastern India: An Observational Study.",
        "abstract": "Tropical sprue TS infection caused iHelicobacter pylorii frequent cause morbidity tropics disease entities apart common regional distribution probably also share hosts sometimes exhibit symptom overlap likely modify others course data supporting association scant may testify association causing human suffering enrolled 67 patient dyspepsia also associated history suggestive malabsorption any two following chronic diarrhea greater four week andor unintentional significant weight loss 5 body weight three month andor nutritional deficiency iron B12 folate various proportions presented gastroenterology referral OPD tertiary care hospital northeastern region India period two half years patient incorporated informed consent fulfilling inclusion exclusion criteria initially underwent battery blood stool test exclude prevalent cause malabsorption followed upper gastrointestinal endoscopy additional rapid urease testing RUT wherever indicated mandatory biopsy taken stomach corpus antrum second part duodenum significant 53 67 patient found iH pylorii infection as diagnosed endoscopic findings RUT histopathological examination gastric biopsies concurrent feature TS duodenal biopsies Literature supporting close association TS iH pylorii scarce presentation TS dyspepsia peculiar unusual study offer new insight symptom overlap coexistence iH pylorii infection TS patient presenting iH pylorii infection feature malabsorption clinically prudent evaluate underlying TS ensure inclusive effective treatment approach",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40777715/",
        "source_type": "Global"
    },
    {
        "pmid": "40777656",
        "title": "Machine learning algorithms to predict feeding practices during diarrheal disease and its determinants among under-five children in East Africa.",
        "abstract": "Diarrhea leading cause childhood malnutrition Although replacement continued feeding increasing appropriate fluid home diarrhea episode cornerstone treatment packages food fluid restriction common diarrheal illness Africa fill methodological current evidence gaps study aimed build model predict determinant increase feeding practice child East Africa diarrheal outbreaks used recent demographic health survey DHS statistic 12 East African nation collected 2012 2023 analysis included total weighted sample 20059 child aged 5 years Python software utilized data processing machine learning model building employed four ML algorithms Random Forest RF Decision Tree DT XGB Extreme Gradient Boosting Logistic Regression LR work evaluated predictive models performance using performance assessment criterion accuracy precision recall AUC curve study 20059 child aged 5 year used final analysis Among proposed machine learning models random forest performed best overall proposed classifier accuracy 9786 precision 98 recall 77 Fmeasure 86 AUC curve 97 significant determinant increasing feeding practice richest household faculty delivery use modern contraception method number child 35 womens employment status maternal age 2534 medium exposure healthseeking decision made mother associated positively whereas using contraception home delivery total number child large sex household male associated negatively feeding practice diarrhea East Africa Machine learning ML algorithm provided valuable insight complex factor influencing feeding practice diarrheal disease underfive child East Africa diarrhea 11 100 child received acceptable child feeding practices onethird patient received less usual nothing Reducing diarrhearelated child mortality improving diarrhea management practice recommended particularly focusing identified aspects",
        "mesh_terms": [
            "Humans",
            "Machine Learning",
            "Child, Preschool",
            "Female",
            "Diarrhea",
            "Male",
            "Africa, Eastern",
            "Infant",
            "Algorithms",
            "Feeding Behavior"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40777656/",
        "source_type": "Global"
    },
    {
        "pmid": "40774377",
        "title": "Iconographic validation of the Bristol scale in patient with neurological diseases.",
        "abstract": "Bristol Stool Scale published Heaton et al 1988 population patient suffering irritable bowel syndrome selfassessment tool estimate stool appearance therefore transit timeIt widely used scale recommended 2016 ROME IV criterion diagnose chronic constipationAlthough initially validated large population patient gastrointestinal disorders specific evaluation population suffering neurological disease never validated Subjects asked orally categorize nine color photo stool various consistencies viewed computer screen according Bristol scale provided paper color authorization obtained Rome Foundation use scale study Then asked comprehension scale acceptability completeness difficulty position single categoryThe primary endpoint agreement subjects response intraclass agreement coefficient ICC scoring sample stool photograph Bristol scaleSecondary end point comprehension acceptability appropriateness collected qualitative interview subjects calculated intraclass correlation index 092 stool photograph extremity scale Bristol 1 7 subject response sameThe scale considered difficult understood well accepted population Bristol scale used subject neurological diseases well understood accepted population helpful management rehabilitation medical treatment constipation andor fecal incontinence observed population",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40774377/",
        "source_type": "Global"
    },
    {
        "pmid": "40773042",
        "title": "Safety Assessment and Efficacy of Probiotic Bacillus clausii PBC429™ (MTCC 25459) for Management of Diarrhea.",
        "abstract": "study evaluated vivo safety rat efficacy probiotic strain Bacillus clausii shouchella clausi PBC429™ mouse treatment diarrhea acute toxicity study single oral dose 2000 mgkg 500 × 10sup9sup CFUg administered rats followed subacute toxicity study 28 day repeated oral administration Bacillus clausii PBC429™ dose 250 500 1000 mgkgday present study two dos Bacillus clausii PBC429™ tested mouse castor oilinduced diarrhea result study indicate toxic effect Bacillus clausii PBC429™ observed dose administered 28 days significant change body weight clinical signs hematological examinations clinical biochemistry gross pathology histopathology observed control test groups Based results NOAEL found 2000 mgkg 1000 mgkg 5 × 10sup11sup CFU respectively Bacillus clausii PBC429™ reduced frequency defecation onset diarrhea total fecal weight percentage defecation Thus result study suggest Bacillus clausii safe human consumption effective antidiarrheal agent",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40773042/",
        "source_type": "Global"
    },
    {
        "pmid": "40772207",
        "title": "Comparative Efficacy and Toxicity of Modified FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma: A Real-World Retrospective Analysis.",
        "abstract": "Background Pancreatic ductal adenocarcinoma PDAC remains highly lethal malignancy limited effective systemic therapies Modified FOLFIRINOX mFOLFIRINOX gemcitabine plus nabpaclitaxel GN commonly used firstline regimens purpose study evaluate realworld efficacy response rates progressionfree survival PFS overall survival OS toxicity grade 34 hematologic nonhematologic toxicities firstline mFOLFIRINOX gemcitabine plus nabpaclitaxel patient advanced pancreatic ductal adenocarcinoma Methods conducted retrospective analysis 64 patient advanced PDAC treated May 2023 May 2025 Thirty patient received GN 34 received mFOLFIRINOX Efficacy outcome included overall response rate ORR clinical benefit rate CBR PFS OS Toxicities graded using Common Terminology Criteria Adverse Events CTCAE v40 Statistical analysis included KaplanMeier survival estimate Cox regression modeling Results median age 59 year range 3275 predominance male patient 682 Eastern Cooperative Oncology Group Performance Status ECOG PS 01 891 Patients receiving mFOLFIRINOX younger likely tumor pancreatic head whereas elevated CA199 level common GN group ORR 57 GN arm 529 mFOLFIRINOX P0179 CBR comparable 77 vs 765 P0985 median progressionfree survival patient receiving GN 697 month 85 month FOLFIRINOX HR 114 95 CI 058  222 P0713 mFOLFIRINOX median overall survival benefit HR 1352 95 CI 063  290 P0428 reach statistical significance Oneyear OS higher mFOLFIRINOX 916 vs 824 15year OS 763 vs 550 Paradoxically oneyear PFS favored GN 325 vs 203 Grade 34 hematologic toxicity frequent mFOLFIRINOX eg neutropenia 20 vs 88 anemia 20 vs 59 GN associated grade 34 vomiting 382 vs 10 P0009 diarrhea 265 vs 33 P0011 neuropathy 294 vs 67 P002 Dose modification treatment delay similar though delay frequent mFOLFIRINOX arm Conclusions mFOLFIRINOX GN demonstrated comparable efficacy realworld treatment advanced PDAC mFOLFIRINOX offered better longterm OS carried higher risk hematologic toxicity GN associated greater gastrointestinal neurological adverse effects Treatment selection guided patientspecific factor comorbidities tolerance toxicity Sequential treatment planning including access secondline therapy significantly impact survival integral care strategies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40772207/",
        "source_type": "Global"
    },
    {
        "pmid": "40772201",
        "title": "Adult Hemolytic Uremic Syndrome as a Diagnostic Challenge.",
        "abstract": "Hemolytic uremic syndrome HUS rare serious condition adults typically characterized triad microangiopathic hemolytic anemia MAHA thrombocytopenia acute kidney injury AKI commonly associated pediatric population Shiga toxinproducing iEscherichia colii STEC adultonset case remain underrecognized especially resourcelimited setting like India report case 35yearold male patient presented lowgrade fever bloody diarrhea jaundice dark browncolored urine Laboratory evaluation revealed MAHA hemoglobin 98 gdL schistocytes 2 elevated lactate dehydrogenase thrombocytopenia platelet count 45400mm³ acute kidney injury AKI serum creatinine 045 mgdL initially transient rise Notably direct bilirubin disproportionately elevated 65 mgdL raising suspicion hepatic involvement Blood culture grew iEscherichia colii iE colii though stool culture negative Peripheral smear elevated reticulocyte count absence disseminated intravascular coagulation DIC supported diagnosis typical HUS ADAMTS13 levels complement assays stool Shiga toxin testing unavailable patient also severe vitamin B12 deficiency raising consideration pseudothrombotic microangiopathy pseudoTMA concurrently treated later developed noncardiogenic pulmonary edema managed corticosteroid supportive therapy discharged hematinics followup two month revealed hemoglobin improvement 102 gdL full renal recovery case highlight diagnostic therapeutic challenge adult HUS especially overlapping feature pseudoTMA potential infectious triggers absence definitive diagnostic modality like ADAMTS13 testing necessitated reliance clinical scoring peripheral smear exclusion mimickers elevated direct bilirubin rare pulmonary involvement broadened clinical complexity Early recognition supportive care led favorable outcomes Yet inability completely exclude atypical cause iStreptococcus pneumoniaeiassociated HUS SpHUS B12 deficiency imposes clinical challenge Adult HUS remains diagnostic challenge due rarity atypical presentations limited access confirmatory testing many settings case emphasizes need systematic evaluation awareness differential diagnosis like pseudoTMA SpHUS timely supportive management also contributes growing literature adult HUS India underscoring importance clinical vigilance atypical hemolytic syndromes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40772201/",
        "source_type": "Global"
    },
    {
        "pmid": "40771267",
        "title": "Secondary Dengue Infection Complicated by Hemophagocytic Lymphohistiocytosis: A Case Report.",
        "abstract": "Hemophagocytic lymphohistiocytosis fatal hyperinflammatory disorder CD8 cytotoxic Tcells natural killer cells macrophage destroy hematopoietic cell vital organs Viral infections EpsteinBarr virus known cause secondary hemophagocytic lymphohistiocytosis adult patients However despite rarity dengue virus identified potentially cause hemophagocytic syndrome associated significant mortality morbidity Herein present case report 52yearold male patient presented fevers worsening nonbloody copious diarrhea excessive fatigue nausea vomiting known sickle cell trait diagnosis hemophagocytic lymphohistiocytosis confirmed liver biopsy accompanied elevated ferritin level 33539 ngmL IL2R level 59442 pgmL thrombocytopenia 49 kμL anemia hemoglobin mean corpuscular volume 73 gdL 773 fL elevated bilirubin total bilirubin 32 mgdL addition elevated IgG IgM antibody determined reinfection dengue virus administration dexamethasone etoposide additional supportive medication initiated Despite efforts patients neurological status declined patient died case dengueinduced hemophagocytic lymphohistiocytosis worrisome challenging diagnostic condition primarily due similarity symptom hemophagocytic lymphohistiocytosis dengue hemorrhagic fever Treatment delay may inevitable consequence Differentiating dengue hemorrhagic fever dengueinduced hemophagocytic lymphohistiocytosis requires evaluating clinical laboratory biopsy findings role sickle cell trait unknown presentation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40771267/",
        "source_type": "Global"
    },
    {
        "pmid": "40771189",
        "title": "Cerebrotendinous Xanthomatosis Disease Prevalence in Patients with Autism Spectrum Disorder: A Prospective Observational Study.",
        "abstract": "Cerebrotendinous xanthomatosis CTX autosomal recessive congenital metabolic disorder characterized impairment enzymatic activity sterol 27hydroxylase CTX rare neurodegenerative disease sterol metabolism affect multiple systems including nervous system demonstrated many congenital metabolic disease like CTX associated autism spectrum disorder ASD aim study identify prevalence CTX disease patient ASD clinical condition patient evaluated using Mignarri Scoring Index sociodemographic form Gilliam Autism Rating Scale2 applied participants total 101 child adolescent ASD analyzed genes Following genetic analyses 4 patient mutation iCYP27A1i gene two homozygous variants two different heterozygous mutation identified common symptom diarrhea Overall 673 patient 3 4 case iCYP27A1i gene mutation gone psychiatric evaluation family history psychiatric disorder present 198 case 75 case mutations Moreover mutant case comorbid oppositional defiant disorder total 812 patient mutant patient diagnosed behavioral disorder Psychiatric manifestation ranging personality change behavioral disorder might accompany CTX Better understanding knowledge CTX disease distinguishing specific psychiatric systemic symptom might help prevent missed diagnoses progressive neurological deterioration permanent disability early initiation chenodeoxycholic acid treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40771189/",
        "source_type": "Global"
    },
    {
        "pmid": "40770648",
        "title": "Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.",
        "abstract": "PI3KAKT pathway frequently altered advanced triplenegative breast cancer aTNBC representing promising target Ipatasertib panAKT inhibitor shown activity taxanebased chemotherapy acceptable safety study evaluated safety efficacy ipatasertib nontaxane chemotherapy aTNBC PATHFINDER trial multicenter openlabel noncomparative phase IIa study safety runin phase Eligible patient TNBC pretreated advanced setting one two chemotherapy regimens including taxane prior exposure PI3KmTORAKT inhibitors Patients received 21day cycle ipatasertib combined capecitabine arm A eribulin arm B carboplatin plus gemcitabine arm C safety runin phase determined feasibility phase IIa doses primary endpoint incidence treatmentemergent adverse event TEAEs Key secondary endpoint included progressionfree survival PFS overall survival OS objective response rate ORR analysis exploratory without formal hypothesis testing total 54 patient assigned arm N  22 B N  25 C N  7 Arm C discontinued due toxicity safety runin phase data cutoff November 2023 overall median followup 121 range 02356 months Common TEAEs arm diarrhea 591 00 G ≥ 3 fatigue 364 00 G ≥ 3 nausea 364 00 G ≥ 3 arm B neutropenia 520 320 G ≥ 3 diarrhea 520 40 G3 stomatitis 440 80 G3 arm C thrombocytopenia 857 857G ≥ 3 anemia 857 571 G ≥ 3 neutropenia 714 714 G ≥ 3 treatmentrelated death occurred Median PFS 27 95CI 1541 38 95CI 1596 months median OS 155 95CI 118193 115 95CI 88251 months ORR 91 360 arm B respectively significant difference efficacy observed PIK3CA mutational status Ipatasertib combined capecitabine eribulin showed acceptable safety tolerable carboplatin plus gemcitabine addition ipatasertib capecitabine eribulin show potential efficacy signal patient population compared historical monotherapy data treatments Identifying biomarkers predict response AKT inhibitor TNBC crucial www gov  NCT04464174 Registered 09 July 2020",
        "mesh_terms": [
            "Humans",
            "Female",
            "Triple Negative Breast Neoplasms",
            "Middle Aged",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Adult",
            "Aged",
            "Capecitabine",
            "Carboplatin",
            "Pyrimidines",
            "Furans",
            "Ketones",
            "Gemcitabine",
            "Deoxycytidine",
            "Progression-Free Survival",
            "Polyether Polyketides",
            "Piperazines"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40770648/",
        "source_type": "Global"
    },
    {
        "pmid": "40769686",
        "title": "Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.",
        "abstract": "introduction daratumumablenalidomidedexamethasone firstline treatment patient newly diagnosed transplantineligible multiple myeloma lenalidomidedexamethasone standard care aimed explore whether addition secondgeneration proteasome inhibitor carfilzomib lenalidomidedexamethasone improved rate measurable residual disease MRD negativity progressionfree survival EMN20 randomised openlabel multicentre phase 3 trial comparing weekly carfilzomiblenalidomidedexamethasone versus lenalidomidedexamethasone patient newly diagnosed transplantineligible multiple myeloma conducted 27 centre Italy Key inclusion criterion included fit intermediatefit status according International Myeloma Working Group IMWG frailty score measurable disease according IMWG criteria Eastern Cooperative Oncology Group performance status lower 3 Patients randomly assigned carfilzomiblenalidomidedexamethasone group received 28day carfilzomiblenalidomidedexamethasone cycle carfilzomib 20 mgmsup2sup intravenously day 1 cycle 1 followed 56 mgmsup2sup intravenously day 8 15 cycle 1 56 mgmsup2sup intravenously day 1 8 15 cycle 212 56 mgmsup2sup intravenously day 1 15 cycle 13 5 year randomisation lenalidomide 25 mg orally day 121 disease progression intolerance dexamethasone 40 mg orally day 1 8 15 22 disease progression intolerance Patients assigned lenalidomidedexamethasone group received 28day cycle lenalidomidedexamethasone same dosing schedule used carfilzomiblenalidomidedexamethasone group Primary endpoint MRD negativity nextgeneration sequencing sensitivity 10sup5sup 2 year treatment progressionfree survival assessed intentiontotreat ITT population all patient eligible receive treatment randomly assigned one treatment groups Nov 23 2021 enrolling 30 planned patient 101340 trial prematurely stopped due introduction daratumumablenalidomidedexamethasone firstline treatment Italy caused lenalidomidedexamethasone control group longer considered standard treatment trial registered ClinicalTrialsgov NCT04096066 study recruitment complete Nov 14 2019 Nov 23 2021 82 101 enrolled patient assessed eligibility randomised receive carfilzomiblenalidomidedexamethasone n42 lenalidomidedexamethasone n40 ITT population 35 43 82 patient female 47 57 male data cutoff March 29 2024 median followup 35·2 month IQR 30·338·7 2year MRD negativity rate 25 60 95 CI 4374 42 patient carfilzomiblenalidomidedexamethasone versus 0 0 09 40 patient lenalidomidedexamethasone p0·0001 Median progressionfree survival reached not reachednot reached carfilzomiblenalidomidedexamethasone versus 20·9 month 15·7not reached lenalidomidedexamethasone hazard ratio 0·24 95 CI 0·110·56 p0·00084 One patient excluded safety analysis died starting treatment frequent grade 3 worse adverse event neutropenia nine 22 41 patients thrombocytopenia four 10 diarrhoea four 10 cardiac event three 7 infection three 7 arterial hypertension two 5 carfilzomiblenalidomidedexamethasone neutropenia six 15 40 skin rash four 10 lenalidomidedexamethasone common serious adverse event SARSCoV2related pneumonia carfilzomiblenalidomidedexamethasone group two 5 41 patients lenalidomidedexamethasone group three 7 40 patients Treatmentemergent adverse event leading death observed two patient carfilzomiblenalidomidedexamethasone two SARSCoV2 infections four patient lenalidomidedexamethasone group one acute myocardial infraction one heart failure one septic shock one SARSCoV2 infection limitation smaller sample size planned due trials early interruption results knowledge showed firsttime high rate MRD negativity weekly carfilzomib added lenalidomidedexamethasone patient transplantationineligible newly diagnosed multiple myeloma carfilzomiblenalidomidedexamethasone group higher MRD negativity rate associated progressionfree survival advantage lenalidomidedexamethasone Toxicities predictable generally manageable Amgen Bristol Myers Squibb",
        "mesh_terms": [
            "Humans",
            "Multiple Myeloma",
            "Lenalidomide",
            "Dexamethasone",
            "Male",
            "Female",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Aged",
            "Middle Aged",
            "Oligopeptides",
            "Transplantation, Autologous"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40769686/",
        "source_type": "Global"
    },
    {
        "pmid": "40769540",
        "title": "[Research progress in active substances and their mechanisms of action against porcine epidemic diarrhea virus].",
        "abstract": "Porcine epidemic diarrhea virus PEDV intestinal coronavirus cause porcine epidemic diarrhea leading diarrhea vomiting weight loss even death piglets Due diversity PEDV strains traditional vaccine difficult sustainably effectively prevent control PEDV article review strategy mechanism active substance regulating intracellular signaling pathways viral proteins microbial metabolite enhance host immune function PEDV emphasizes prevention PEDV resistance potential harm PEDV breaking interspecies barrier human society aiming provide reliable theoretical support development new antiviral drug vaccines",
        "mesh_terms": [
            "Porcine epidemic diarrhea virus",
            "Animals",
            "Swine",
            "Swine Diseases",
            "Antiviral Agents",
            "Coronavirus Infections",
            "Viral Vaccines",
            "Humans",
            "Signal Transduction"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40769540/",
        "source_type": "Global"
    },
    {
        "pmid": "40769220",
        "title": "Chrysin inhibits PEDV replication by antagonizing apoptosis via the ROS/JNK/p53 axis.",
        "abstract": "Porcine epidemic diarrhea virus PEDV remains significant threat global swine industry immunization strategy limited viral genome variation lack effective therapeutic drugs flavonoid compound chrysin shown potential antiPEDV activity specific antiviral mechanism remain unclear study validated inhibitory effect chrysin PEDV using IFA qPCR Additionally Transcriptome sequencing conducted PEDVinfected Vero cell without chrysin treatment reveal antiviral mechanism result showed 5813 DEGs 12 hpi 3374 DEGs 24 hpi enrichment pathway related transcription translation metabolism innate immunity apoptosis Notably KEGG analysis indicated Chrysin regulate PEDVinduced apoptosis modulating TNF MAPK p53 signaling pathways might antagonize PEDV infection Subsequent result confirmed chrysin significantly downregulate reactive ROS level cell apoptosis rate induced PEDV infection P005 inhibit activation JNK p53 pathways including phosphorylation ASK1 JNK p53 Chrysin also significantly reduced cleaved caspase 389 level BaxBcl2 ratios thereby affecting PEDV N protein expression P  005 Moreover similar inhibitory effect PEDV also achieved JNK inhibitor SP600125 p53 inhibitor PFTα finding revealed chrysin antagonize PEDVinduced apoptosis ROSJNKp53 signaling axis thereby inhibiting viral replication study provides scientific basis developing chrysin novel antiPEDV drug offer insight screening research antiviral drug targets",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40769220/",
        "source_type": "Global"
    },
    {
        "pmid": "40769093",
        "title": "Enhancing pediatric practice: A comprehensive review on malabsorption in pediatrics for diagnostic and management approach.",
        "abstract": "Malabsorption child present significant diagnostic therapeutic challenge due diverse etiology broad spectrum symptoms review aim support pediatric clinician providing structured guide recognizing diagnosing managing malabsorption syndrome children promoting early intervention prevent longterm complications Malabsorption defined inefficient absorption nutrients manifest symptom diarrhea failure thrive systemic nutritional deficiencies etiology categorized intestinal pancreatic hepatobiliary extraintestinal causes necessitating multidisciplinary approach tailored patients age clinical presentation Diagnostic strategy emphasize stool analysis serological testing imaging identify condition Celiac disease Crohns disease exocrine pancreatic insufficiency review explores gastrointestinal systems complexity detailing critical phase digestionluminal mucosal transportand process specific neonate infants Common issue like lactose intolerance small intestinal bacterial overgrowth SIBO bile acid malabsorption addressed alongside rare genetic metabolic disorder require targeted diagnostic approaches Management focus dietary modifications enzyme replacement therapy conditionspecific intervention ensure optimal growth development Special attention given unique challenge neonatal infant cases developmental immaturity congenital disorder often complicate evaluation treatment synthesizing current evidence clinical guidelines review provides pediatrician practical framework addressing multifaceted challenge malabsorption emphasizes importance early recognition multidisciplinary care improve patient outcome quality life",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40769093/",
        "source_type": "Global"
    },
    {
        "pmid": "40768480",
        "title": "Economics of vaccination against diarrhoea and respiratory diseases in French cow calves' systems: A modelling approach.",
        "abstract": "assess economic benefit vaccination diarrhoea respiratory disease cowcalf systems stochastic mechanistic mathematical programming bioeconomic model developed beef Charolais breed farm model reproduced herd dynamic weekly basis 10year period including animal growth reproduction disease risk control treatments vaccination Three baseline risk level diarrhoea respiratory disease considered simulate low average high infection risk farm result demonstrated models ability reproduce average farm dynamics diarrhoea prevalence ranging 8 33 respiratory disease 13 79 average prevalence decreased 24 50 respectively due vaccination also reduced 2day 1month mortality rate 23 1517 respectively net value vaccination positive except case low infection risk diarrhoea respiratory diseases return investment ROI vaccination 0405 €1 invested yield €0405 baseline scenario middle infection risks negative low infection risks reached 1 €1 invested yield €1 high infection risks result also showed farmer may earn €5875 additional revenue per extra hour labour dedicated vaccination mediumrisk scenario Despite limited availability data cowcalf systems study demonstrated economic benefit vaccination combination scenario risks profitability vaccination challenged low disease risk considered cases vaccination may serve insurance financial loss case health status deterioration",
        "mesh_terms": [
            "Cattle",
            "Animals",
            "Vaccination",
            "Diarrhea",
            "Cattle Diseases",
            "Models, Economic",
            "France",
            "Respiratory Tract Diseases",
            "Cost-Benefit Analysis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40768480/",
        "source_type": "Global"
    },
    {
        "pmid": "40768129",
        "title": "Computational exploration and molecular dynamics simulations for investigating the potential inhibitory mechanism of amantadine on the ion channel activity of bovine viral diarrhea virus p7.",
        "abstract": "Bovine viral diarrhea virus BVDV p7 function viroporin ion balance membrane permeabilization Blocking function viroporin promising strategy treatment viral infection Previous study demonstrated antiviral drug amantadine inhibits BVDV replication inhibiting BVDV p7 activity However mechanism amantadine act BVDV p7 remains unclear study AlphaFold2 molecular docking molecular dynamic MD simulation employed investigate binding site amantadine BVDV p7 Structural analysis AlphaFold2 MD simulation showed BVDV p7 may undergo antiparallel oligomerization forming stable hexamer generates pore channel Notably residue E21 Y25 L28 R34 within channel likely involved ion transport Subsequently interaction amantadine BVDV p7 hexamer investigated docking study MD simulation analysis indicating residue Y25 L28 van der Waals forces alkyl PiAlkyl interaction amantadine Importantly hydrogen bonding observed NHsub3subsupsup group amantadine residue Y25 integrating finding potential hexameric assembly BVDV p7 proposed potential ion channel model E21 Y25 R34 hypothesized selectively recruit dehydrate ions residue L28 act hydrophobic restrictor limiting free movement water binding amantadine residue Y25 L28 likely disrupts ion transport finding provide possible structural insight BVDV p7 ion channel offer mechanistic explanation inhibitory amantadine BVDV p7mediated ion channel conductance though experimental validation remains necessary",
        "mesh_terms": [
            "Amantadine",
            "Molecular Dynamics Simulation",
            "Antiviral Agents",
            "Molecular Docking Simulation",
            "Binding Sites",
            "Animals",
            "Ion Channels",
            "Viral Proteins",
            "Diarrhea Viruses, Bovine Viral",
            "Cattle",
            "Hydrogen Bonding",
            "Protein Binding"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40768129/",
        "source_type": "Global"
    },
    {
        "pmid": "40767981",
        "title": "Bifidobacteria in antibiotic-associated dysbiosis: restoring balance in the gut microbiome.",
        "abstract": "Antibioticassociated dysbiosis disrupts guts microbial balance leading reduced diversity overgrowth antibioticresistant strains compromised gut homeostasis result inflammation increased intestinal permeability impaired immunity heightened susceptibility infections context probiotic highlighted promising remedy alleviating antibioticinduced gut microbiome aberration subsequent decrease detrimental effects Bifidobacteria prominent bacterial group promising probiotic attributes shown effectiveness restoring gut microbiome strong adherence colons mucosal lining enhancing immune response increased antiinflammatory cytokines also play crucial role key producer acetic acid support butyric acidproducing bacteria essential colonocyte health dysbiosis synergistic use bifidobacteria probiotic specie prebiotic substrate enhanced survival colonization capacity overall impact gut microbial restoration Advanced metagenomic analysis begun reveal strainspecific functions paving way personalized probiotic therapy tailored individuals unique microbiome profile Despite encouraging progress critical research gap persist particularly regarding strainspecific efficacy formulation stability longterm outcomes underlying mechanisms systemic interactions distinct specific role bifidobacteria Addressing gap targeted clinical investigation essential fully harness therapeutic potential develop optimized strategy restoring microbial balance gut microbiome",
        "mesh_terms": [
            "Dysbiosis",
            "Humans",
            "Probiotics",
            "Gastrointestinal Microbiome",
            "Bifidobacterium",
            "Anti-Bacterial Agents",
            "Animals",
            "Prebiotics"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767981/",
        "source_type": "Global"
    },
    {
        "pmid": "40767957",
        "title": "[Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine].",
        "abstract": "Glucagonlike peptide‑1 receptor agonist GLP‑1 RA semaglutide tirzepatide originally developed treatment type 2 diabetes shown significant weight loss effects led increasing offlabel use esthetic weight reduction associated facial changes particularly volume loss skin laxity increased wrinkle formation gaining attention plastic esthetic medicine study review current literature GLP‑1 RAs esthetic effect potential therapeutic approaches selective literature review GLP‑1 RAs conducted focusing mechanism action clinical effects offlabel use esthetic consequence treatment options use GLP‑1 RAs promotes weight loss regulating appetite delaying gastric emptying Frequent side effect include gastrointestinal symptoms nausea vomiting diarrhea obstipation possible association thyroid tumor remains unclear increasing offlabel use led supply shortage regions Esthetic changes termed Ozempic face include volume loss skin laxity pronounced wrinkles Treatment option discussed literature include noninvasive highintensity focused ultrasound HIFU radiofrequency minimally invasive fillers biostimulators surgical procedure facelifting fat grafting rising offlabel use GLP‑1 RAs present new challenge esthetic medicine Rapid fat loss result pronounced facial changes driving demand corrective interventions however systematic study effectiveness safety treatment lacking research needed develop evidencebased strategy standardized guideline esthetic management affected patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767957/",
        "source_type": "Global"
    },
    {
        "pmid": "40767554",
        "title": "PgtE protease enables virulent <i>Salmonella</i> to evade C3-mediated serum and neutrophil killing.",
        "abstract": "Nontyphoidal iSalmonellai serovars iSalmonella entericai serovar Typhimurium STm leading cause inflammatory diarrhea otherwise healthy individuals Among children elderly immunocompromised individuals STm spread systemic site cause potentially lethal bacteremia Phagocytic cell immune complement system pivotal preventing dissemination STm PgtE STm outer membrane protease previously described cleave dozen mammalian protein substrate iin vitroi including complement protein C3 However activity mostly observed mutant avirulent strain truncated Oantigen render bacteria sensitive complement killing Here report virulent STm utilizes PgtE evade complementmediated killing iin vivoi wildtype pathogen increase ipgtEi expression PgtE proteolytic function within macrophage macrophagelike iin vitroi growth conditions concomitant physiologic Oantigen truncation environments Furthermore found wildtype STms resistance complementmediated serum neutrophil killing PgtEdependent propose PgtE promotes systemic spread STm acting second line defense complement STm escape macrophageIMPORTANCENontyphoidal iSalmonellai serovars primarily cause gastrointestinal infection also lead bacteremia mechanism completely elucidated show outer membrane protease PgtE enables virulent iSalmonellai evade complementmediated killing iin vivoi thereby promoting bacteremia also demonstrate ipgtEi expression PgtE proteolytic function increased within macrophage macrophagelike growth conditions Upon escaping macrophages PgtE protects complementmediated killing serum neutrophils promoting systemic spread pathogen finding highlight PgtE potential therapeutic target preventing iSalmonellai bacteremia",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767554/",
        "source_type": "Global"
    },
    {
        "pmid": "40767453",
        "title": "Sheehan's syndrome complicated with Graves' disease in a woman with a 20-year history of hypothyroidism.",
        "abstract": "Sheehans syndrome disorder caused ischemic necrosis pituitary gland following postpartum hemorrhage typically resulting pituitary dysfunction affect adrenal thyroid gonadal axes Clinically patient may present dysfunction single axis multiple axes cooccurrence Sheehans syndrome Graves disease extremely rare posing significant diagnostic challenge Herein report case woman early 50 28year history Sheehans syndrome led complete pituitary dysfunction managing hypothyroidism past 20 years However 6month period developed chronic diarrhea showed progressive weight loss laboratory result indicating hyperthyroidism Based imaging laboratory findings along medical history diagnosis Sheehans syndrome complicated Graves disease established evidenced elevated level thyrotropin receptor antibodies Treatment included adrenocorticotropic hormone replacement antithyroid therapy supportive measures Although gastrointestinal symptom weight loss resolved initially patient continued experience persistent hyperthyroidism elevated thyrotropin receptor antibody level 20month followup case highlight need regular endocrine monitoring patient Sheehans syndrome particularly longstanding hypothyroidism promptly identify address potential overlap autoimmune thyroid diseases",
        "mesh_terms": [
            "Humans",
            "Female",
            "Graves Disease",
            "Hypothyroidism",
            "Hypopituitarism",
            "Middle Aged"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767453/",
        "source_type": "Global"
    },
    {
        "pmid": "40767428",
        "title": "Current opinion on the management of diarrhea in the HIV infected individual.",
        "abstract": "Diarrhea one main reason morbidity mortality patient HIV especially low middleincome countries review update approach diagnosis management diarrhea patient HIV Duration symptoms characteristic diarrhea smallbowel largebowel type presence constitutional symptom current CD4 cell count important parameter noted history give important clue diagnosis Multiple pathogen coexist severely immune compromised patients Stool microscopy modified AFB trichrome stains though standard largely replaced multiplex PCR except resource limited settings Computerized tomography scan helpful constitutional symptoms endoscopic biopsy remains gold standard noninvasive test nondiagnostic Diagnostic workup negative subset HIV population could due antiretroviral agent HIV per se Treatment involves replacement fluid  electrolyte etiologyappropriate antimicrobials ART optimized patients often result clinical improvement Managing chronic diarrhea HIV positive patient requires multimodal approach usually successful even resourcelimited setting provided access ART available",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767428/",
        "source_type": "Global"
    },
    {
        "pmid": "40767317",
        "title": "GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial.",
        "abstract": "GLY200 investigational oral polymeric drug designed enhance barrier function gastrointestinal mucus noninvasive alternative metabolic surgery study evaluated safety tolerability pharmacodynamic effect GLY200 patient T2D phase 2 placebo PBOcontrolled doubleblind singlecentre inpatient study ClinicalTrialsgov NCT05478525 enrolled patient n  51 aged 3070 year T2D HbA1c ≥60 85 stable metformin ≥750 mgday ≥3 months Patients received 14 day twice day BID 05 10 20 g GLY200 PBO 1111 primary endpoint safety tolerability Additional endpoint included change plasma glucose secondary calorie lipid profile exploratory GLY200 appeared safe well tolerated frequently related TEAEs subject treated GLY200 constipation nausea diarrhoea vomiting mild Improvements fasting postprandial glucose observed 20 g Day 14 postprandial glucose poststandardized meal mean absolute AUCsub03HRsub difference PBO 17833 mgdLhr 95 CI 32716 2950 p  002 Csubmaxsub difference 5088 mgdL 10023 154 p  004 Day 14 mean change baseline fasting serum glucose 20 g group 161 SD 225 versus 121 418 mgdL PBO group GLY200 treatment also resulted numerical reduction food intake modest decrease body weight improvement lipid profile consistent duodenal exclusion mechanism result suggest duodenal exclusion possible oral polymeric drug support development GLY200 treatment T2D obesity",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767317/",
        "source_type": "Global"
    },
    {
        "pmid": "40766846",
        "title": "Helile formula from \"Tai ping sheng hui fang<i>\"</i>: anti-<i>Helicobacter pylori</i> activity, gut microbiota modulation, and inflammatory response regulation.",
        "abstract": "iHelicobacter pylorii HP major gastric pathogen linked chronic gastritis peptic ulcers gastric cancer emergence antibiotic resistance prompted search alternative treatments Helile formula derived ancient Taiping Shenghuifang known treat various degree diarrhea potential treating gastrointestinal disorders However antibacterial efficacy material basis action mechanism helile formula HP remain undetermined chemical constituent analyzed using ultrahighperformance liquid chromatographytandem mass spectrometry UPLCMSMS highperformance liquid chromatography HPLC iin vitroi antiHP activity underlying mechanism investigated series assays including determination minimum inhibitory concentration MIC Nphenyl1naphthylamine NPN uptake assay scanning electron microscopy SEM observe morphological changes cell viability cell adhesion activity assays assessment nitric oxide NO production reverse transcriptionquantitative polymerase chain reaction RTqPCR gene expression analysis iin vivoi antiHP infection study mechanism exploration technique hematoxylin eosin HE staining histological examination enzymelinked immunosorbent assay ELISA cytokine antibody quantification 16S ribosomal DNA 16S rDNA sequencing microbial community profiling metabolomics global metabolite analysis employed Multiple constituent helile formula namely ellagic acid gallic acid chebulagic acid chebulic acid corilagin identified iIn vitroi helile formula increased bacterial outermembrane permeability disrupted HP structure inhibited toxinrelated genes suppressed cell adhesion male Kunming mice helile formula effectively reversed HPinduced inflammation modulated key metabolites adenine panaxytriol 4hydroxyglutamate semialdehyde NalphaAcetylLlysine influenced gut microbiota especially family like iMuribaculaceaei iLactobacillaceaei Adenine particular repaired HPcaused damage GES1 cells reduced HP  mediated cell adhesion inhibited HPinduced interleukin6 IL6 tumor necrosis factoralpha TNFα production finding demonstrated remarkable antiHP efficacy helile formula iin vitroi iin vivoi suggesting helile formula represents highly promising therapeutic candidate management HP infections",
        "mesh_terms": [
            "Helicobacter pylori",
            "Animals",
            "Gastrointestinal Microbiome",
            "Helicobacter Infections",
            "Mice",
            "Anti-Bacterial Agents",
            "Microbial Sensitivity Tests",
            "Disease Models, Animal",
            "Drugs, Chinese Herbal",
            "Humans",
            "Nitric Oxide",
            "Male",
            "Cell Survival",
            "Inflammation",
            "Tandem Mass Spectrometry",
            "Cytokines"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40766846/",
        "source_type": "Global"
    },
    {
        "pmid": "40765987",
        "title": "Na we go shine: women's wellbeing, agency, and health seeking behaviours in southeastern Nigeria.",
        "abstract": "Peerreviewed literature southeastern Nigerian womens health status scant participatory action research project explored mental physical health status issue within sample population childbearing woman Cross River State conducted initial study using formal chieftaincy channel village learned expressed primarily men found concern differed women conducted study attempt hear woman health need context lives Local woman carried facetoface interview language childbearing woman community interviewed 70 woman age 1845 12 villages participant farm grew rice cassava yam feed families majority participant completed elementary school given birth average 6 children 4 survived woman included study walked 68 h per day retrieve drinking water young child baby often accompanied mother journeys Participants reported suffered malaria diarrhea anemia hernia waist pains cough eye problem continuous headaches Traditional healer first choice treatment partly physical financial accessibility partly cultural resonance positive outcomes Despite tremendous social economic political barriers participant generally reported strong sense wellbeing positive outlook lives also interviewed 15 traditional healer enhance statement made female participant regarding healthseeking behaviors",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40765987/",
        "source_type": "Global"
    },
    {
        "pmid": "40765232",
        "title": "Prevalence and toxin gene profiles of <i>Clostridium perfringens</i> in diarrheic dogs and cats in Korea: a retrospective analysis.",
        "abstract": "iClostridium perfringensi significant enteropathogen affecting human animals causing gastrointestinal symptom varying severity including diarrhea dog cats Understanding distribution toxinotypes essential improving diagnostic accuracy treatment strategies study aimed determine prevalence toxin gene profile iC perfringensi strain isolated dog cat diarrhea Republic Korea providing insight regarding predominant toxinotypes iC perfringensiassociated diarrhea Fecal specimen dog cat diarrhea analyzed using multiplex realtime polymerase chain reaction detect various iC perfringensi toxin genes isolates categorized established toxinotype group based toxin gene profiles 110 fecal sample from 50 dog 60 cats majority iC perfringensi isolates classified type A small percentage identified type F Type B C D E isolates found Additionally significant portion isolates carried β2 toxin gene associated pathogenicity considered toxinotype classification Type predominant iC perfringensi toxinotype dog cats type F detected cases finding may aid predicting toxinotypes future diarrhea outbreak support development targeted control measures research required clarify clinical relevance toxinotypes iC perfringensiassociated diarrhea",
        "mesh_terms": [
            "Animals",
            "Cats",
            "Dogs",
            "Clostridium perfringens",
            "Cat Diseases",
            "Dog Diseases",
            "Republic of Korea",
            "Diarrhea",
            "Clostridium Infections",
            "Bacterial Toxins",
            "Retrospective Studies",
            "Prevalence",
            "Feces"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40765232/",
        "source_type": "Global"
    },
    {
        "pmid": "40765227",
        "title": "Clinical utility of two-dimensional shear wave elastography in two dogs with presumptive toxic hepatopathy.",
        "abstract": "Shear wave elastography SWE noninvasive ultrasound technique assessing tissue stiffness study examined clinical utility twodimensional SWE 2DSWE two dog diagnosed presumptive toxic hepatopathy first case involved 9yearold Pompitz presented anorexia vomiting diarrhea following garlic onion ingestion Laboratory test revealed anemia elevated liver enzyme levels diabetic ketoacidosis Ultrasonography demonstrated increased hepatic echogenicity elevated SWE values Despite intensive treatment dogs condition deteriorated progressive increase liver enzyme level SWE values resulting euthanasia second case involved 1yearold Maltipoo presented vomiting depression abdominal pain reported history Laboratory finding indicated elevated liver enzyme bile acid levels Ultrasonography revealed increased hepatic echogenicity SWE values Following treatment acute toxic hepatopathy dog exhibited significant improvement within 3 days normalization hepatic echogenicity SWE values liver enzyme levels case demonstrate clinical relevance 2DSWE assessing hepatic damage tracking therapeutic response informing prognosis presumptive toxic hepatopathy",
        "mesh_terms": [
            "Animals",
            "Dogs",
            "Chemical and Drug Induced Liver Injury",
            "Dog Diseases",
            "Elasticity Imaging Techniques",
            "Liver"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40765227/",
        "source_type": "Global"
    },
    {
        "pmid": "40761974",
        "title": "Enhancing Childhood-Educator Knowledge and Confidence: Virtual \"Coffee Chat\" Interventions with Medical Professionals.",
        "abstract": "Context Early childhood educator ECEs central development care children often lack adequate access resource expert guidance managing common childhood health issues challenge lead significant stress educator parents address gap pilot intervention involving virtual coffee chat session implemented session aimed provide ECEs evidencebased knowledge practical strategy handle frequent childhood health concerns Objective primary objective study enhance knowledge confidence ECEs addressing common health behavioral issue among child New River Valley USA sessions facilitated pediatrician medical students covered range topic identified highpriority educators goal create sustainable educational model improving child health management childcare settings Methods study used selfdesigned pre postsurvey format measure effectiveness eight virtual coffee chat session conducted two years initial session focused educator New River Valley USA final session expanded across Virginia USA Topics included common illness eg cough diarrhea trauma management obesity behavioral issue selfregulation temper tantrums session consisted brief evidencebased presentation followed interactive discussions Participants recruited local statewide child care organizations survey used assess change confidence knowledge levels Descriptive statistic Wilcoxon Signed Rank test applied analyze data qualitative feedback openended response categorized thematically Results Across eight sessions 30 registration recorded 19 participants attended multiple sessions Pre postsurvey result demonstrated significant improvement knowledge confidence overall pvalue 0001 Six eight topic showed increased postsurvey scores session selfregulation temper tantrums largest cohort N10 yielding significant improvement p00041 highlighting broad impact relevance Feedback participant highlighted value practical evidencebased strategy opportunity engage directly healthcare professionals However variability observed topics diarrhea postsurvey score declined slightly pointing potential area improvement Conclusion Virtual coffee chat session proved effective scalable method improving health management skill ECEs interventions interactive accessible format particularly appreciated participant show promise model ongoing professional development However given studys design sample size finding interpreted preliminary Future effort focus refining content expanding participation exploring longterm impact educator practice child outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40761974/",
        "source_type": "Global"
    },
    {
        "pmid": "40761965",
        "title": "Acute Adenoviral Gastroenteritis Complicated by Interstitial Edematous Pancreatitis in an Adult Patient: A Rare Clinical Case With a Multidisciplinary Approach.",
        "abstract": "Adenovirus F type 4041 one significant viral etiological agent acute gastroenteritis young children significant growing cause pediatric gastroenteritis worldwide particularly child age five However rare cases may also lead clinically significant illness adults clinical case present describes course acute adenoviral gastroenteritis complicated acute pancreatitis pronounced intoxication syndrome 24yearold woman Ukraine",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40761965/",
        "source_type": "Global"
    },
    {
        "pmid": "40761476",
        "title": "A Case of Drug-Induced Pancytopenia due to Tamoxifen.",
        "abstract": "Tamoxifen TAM wellestablished treatment hormone receptorpositive breast cancer known sideeffect profile includes hot flashes genital bleeding diarrhea 015 notable side effect include liver damage abnormal vaginal discharge depression dizziness headache unknown frequency However blood cell count reduction yet reported side effect Japan 46yearold female patient diagnosed right breast cancer cT1N0M0 patient underwent partial right breast resection sentinel lymph node biopsy Owing positive surgical resection margin mastectomy performed Pathological analysis surgical specimen confirmed invasive ductal carcinoma estrogen receptor ER 95 progesterone receptor PgR 85 HER2 2 fluorescence iin situi hybridization FISH negative macrometastasis one sentinel lymph node Postoperative treatment included chemotherapy dosedense adriamycin cyclophosphamide AC dosedense paclitaxel PTX irradiation TAM initial blood test result starting TAM showed mild anemia Hb 89 gdL Grade 2 followup blood test 5 month initiating TAM revealed significant decrease blood cell count white blood cell WBC 2600μL Grade 2 neutrophil neu 055 × 10³μL Grade 3 Hb 77 gdL Grade 2 platelet PLT 133 × 10⁴μL Considering onset symptom following TAM administration druginduced pancytopenia suspected TAM concomitant medication pregabalin discontinued However blood cell count continued decline necessitating investigation Myelodysplastic syndrome MDS suspected leading multiple bone marrow biopsies However definitive hematological disorder diagnosed patient received transfusion granulocyte colonystimulating factor GCSF injection based blood cell count Approximately 4 month onset neutropenia gradual recovery observed spontaneous remission occurred Given rarity spontaneous recovery MDS TAM considered potential causative agent observed decline blood cell counts report case suspected druginduced cytopenia associated tamoxifen administration",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40761476/",
        "source_type": "Global"
    },
    {
        "pmid": "40761215",
        "title": "Autoimmune enteropathy in adults: a case report and literature review.",
        "abstract": "Autoimmune enteropathy AIE rare autoimmune disorder characterized primarily villous atrophy small intestinal mucosa article present case adultonset AIE featuring intractable diarrhea severe malnutrition along review existing literature summarize clinical characteristics aiming provide insight diagnosis management AIE 60yearold male admitted due intermittent abdominal pain diarrhea weight loss Laboratory test revealed gliadin immunoglobulin IgA  immunoglobulin G IgG  tissue transglutaminase IgA  IgG  Endoscopy revealed mucous membrane small intestine congested edematous villus atrophied prone bleeding biopsy villus exhibited white mossy appearance Pathologically villus many segment small intestine presented diffuse obvious atrophy lymphocytic infiltration intestinal glands exclusionary diagnosis patient considered AIE effective initial treatment corticosteroid patient exhibited recurrent symptom poor nutritional status eventually died sepsis patient refractory diarrhea intestinal villous atrophy comprehensive diagnosis made based medication history epidemiological factors gluten dietary response serological markers histopathological findings Early intervention corticosteroid combined nutritional support critical vigilance severe adverse event lifethreatening infection essential",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40761215/",
        "source_type": "Global"
    },
    {
        "pmid": "40760599",
        "title": "Silent complication: chronic diarrhea as a clue to gastrojejunocolic fistula: A case report.",
        "abstract": "Gastrocolic fistula represent abnormal connection stomach large intestine often leading chronic diarrhea malnutrition arise postoperatively particularly complex surgery Billroth II procedure case report describes case 71yearold male history hypertension gastrointestinal surgery experienced significant weight loss postprandial diarrhea Initial investigations including stool culture multiple imaging studies failed reveal fistula definitive diagnosis gastrojejunocolic fistula made third gastroscopy endoscope passed stomach colon Surgical intervention involved adhesiolysis resection fistula followed reconstruction gastrointestinal continuity Postoperative care included nutritional support patient showed significant improvement followup case highlight diagnostic challenge associated gastrojejunocolic fistula emphasizes need high index suspicion patient atypical gastrointestinal symptom complex surgery illustrates timely surgical intervention lead positive outcomes underscore importance ongoing research education regarding management complications study needed understand longterm effect gastrojejunocolic fistula optimize management strategies",
        "mesh_terms": [
            "Humans",
            "Male",
            "Aged",
            "Gastric Fistula",
            "Intestinal Fistula",
            "Diarrhea",
            "Chronic Disease",
            "Postoperative Complications",
            "Colonic Diseases",
            "Gastroscopy"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40760599/",
        "source_type": "Global"
    },
    {
        "pmid": "40760469",
        "title": "Pretreatment with an anti-CGRP monoclonal antibody attenuates mild TBI-induced tactile hypersensitivity in mice.",
        "abstract": "Posttraumatic headache PTH develop following mild traumatic brain injury mTBI concussion especially common among activeduty military personnel Veterans athletes high prevalence chronic nature PTH highlight importance studying condition animal model develop new effective treatments Since symptom associated PTH resemble migraine focused neuropeptide calcitonin generelated peptide CGRP potential therapeutic target used mouse model mTBI involving three repeated closed head impact assess therapeutic efficacy monoclonal antibody mAb block CGRP validate model first assessed optimized development periorbital plantar tactile hypersensitivity outbred CD1 mice tested response intraperitoneal injection two migraine triggers CGRP sodium nitroprusside SNP nitric oxide donor Then assessed efficacy antiCGRP mAb using different administration paradigms Early administration antiCGRP mAb induction TBI fully prevent initial transient periorbital tactile hypersensitivity observed following multiple closed head injuries However mAb partially reduce persistent periorbital tactile hypersensitivity subthreshold trigger Administration mAb immediately injury also able partially reduce persistent hypersensitivity Importantly injection antiCGRP mAb 24 h prior injection subthreshold dose CGRP SNP fully prevented periorbital hypersensitivity trigger persistent sensitivity phase result indicate antiCGRP mAb partially fully attenuate cephalic tactile hypersensitivity administered immediately mTBI event contrast stronger rescue seen antiCGRP mAb administered prior CGRP nitric oxide triggers Thus depending timing administration antiCGRP mAb block persistent sensitization headache trigger mTBI online version contains supplementary material available 101186s1019402502108x",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40760469/",
        "source_type": "Global"
    },
    {
        "pmid": "40760061",
        "title": "Nutritional care in metastatic RCC: patient experiences and reported unaddressed needs.",
        "abstract": "Although renal cell carcinoma RCC present unique nutritional challenge due disease treatment side effects little known prevalence nutritional issue among RCC patient realworld setting study aimed investigate patientreported prevalence nutritional issue response healthcare team challenges survey among RCC patient Germany developed collaboration patient organization included 46 question covering demographics nutritional issues cancer care experiences distributed online April July 2022 Responses 94 German RCC patient analyzed using descriptive inferential statistics Nutritional concern reported 606 participants diarrhea 234 loss appetite 213 nausea 202 common issues Unintentional weight loss reported 494 patients 139 referred nutrition specialists twothirds reported negative extremely negative impact due problem physical condition quality life Additionally 67 patient felt nutritional need taken seriously healthcare teams patient 84 think nutritional care part routine cancer care finding reveal significant gap nutritional care RCC patients Screenings proactive assessment appear performed suggested nutritional guidelines Thus nutritional counseling support obviously still integrated realworld comprehensive oncological care",
        "mesh_terms": [
            "Humans",
            "Male",
            "Female",
            "Carcinoma, Renal Cell",
            "Middle Aged",
            "Aged",
            "Germany",
            "Kidney Neoplasms",
            "Quality of Life",
            "Adult",
            "Surveys and Questionnaires",
            "Aged, 80 and over",
            "Nutritional Status",
            "Weight Loss",
            "Diarrhea"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40760061/",
        "source_type": "Global"
    },
    {
        "pmid": "40759997",
        "title": "Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.",
        "abstract": "Atherosclerotic cardiovascular disease ASCVD significantly contribute global mortality especially type 2 diabetes mellitus T2DM necessitating effective preventive strategies Curcumin proposed lower blood pressure glucose level improve lipid profile adjunctive treatment study aimed assess safety efficacy Curcumin supplementation clinical outcome ASCVD risk T2DM patients Seventytwo diabetic patient ASCVD risk score ≥ 5 randomly assigned Curcumin group 500 mg Turmeric curcuminsup®sup thrice daily  conventional therapy Control group conventional therapy only Curcumin significantly reduced SBP DBP P ≤ 0001 P  0020 respectively improved ASCVD risk classification P  0004 LDLC P  0024 TNFα P  0044 MDA P  0028 level decreased HDLC increased P  0024 versus control significant difference found group regarding HbA1c FBG TC TG P  005 Mild adverse effect reported including nausea 139 headache 111 yellow stool 111 diarrhea 56 concluded Curcumin improves ASCVD risk classification lower SBP DBP LDLC TNFalpha MDA increase HDLC well tolerated minor adverse effects without impacting BMI HR HbA1c FBG TC TG",
        "mesh_terms": [
            "Humans",
            "Curcumin",
            "Male",
            "Female",
            "Atherosclerosis",
            "Diabetes Mellitus, Type 2",
            "Middle Aged",
            "Aged",
            "Dietary Supplements",
            "Treatment Outcome",
            "Blood Glucose"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40759997/",
        "source_type": "Global"
    },
    {
        "pmid": "40758717",
        "title": "Mass drug administration for trachoma elimination in a pastoral conflict area in Baringo County, Kenya: A study on barriers to coverage and compliance.",
        "abstract": "Trachoma neglected tropical disease NTD leading infectious cause blindness worldwide caused repeated ocular infection bacteria Chlamydia trachomatis Treatment coverage achieved Baringo County Kenya 2020 2021 80 79 respectively investigation lower level known ward show coverage ranging 48 57 far recommended threshold least 80 target population reached MDA objective study identify barrier community participation access mass drug administration trachoma elimination pastoral conflict area Baringo County Kenya Sixteen focus group discussion conducted community member four among community health volunteers Eight county subcounty leader fourteen opinion leader participated indepth interviews Patients trichiasis took part six micronarrative surveys study participant purposively selected number FGDs interviews micronarrative survey determined saturation model iterative design employed data collection analysis sample selection give early insight influence selection participants Although community member aware trachoma benefit MDA poor knowledge trachoma etiology exists misconception attributing dirt dust flies even witchcraft Women children elderly person perceived higher risk infection remoteness village town hindered awareness creation resulting community member unaware trachoma MDA Side effect like diarrhea nausea headache drowsiness discourage participation Drug size taste perceived negative factors Lack information side effect management contributes hesitancy Considering perspective nomadic people understanding contextspecific risks supporting design communityled intervention critical development effective MDA strategies aid halting trachoma transmission",
        "mesh_terms": [
            "Trachoma",
            "Mass Drug Administration",
            "Neglected Diseases",
            "Disease Eradication",
            "Kenya",
            "Chlamydia trachomatis",
            "Community Participation",
            "Health Knowledge, Attitudes, Practice",
            "Transients and Migrants",
            "Anti-Bacterial Agents",
            "Medication Adherence",
            "Endemic Diseases",
            "Humans",
            "Male",
            "Female",
            "Young Adult",
            "Adult",
            "Middle Aged",
            "Focus Groups",
            "Interviews as Topic",
            "Qualitative Research"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40758717/",
        "source_type": "Global"
    }
]